communityacquir
pneumonia
cap
frequent
infecti
respiratori
diseas
although
mani
patient
cap
treat
outpati
mortal
cap
requir
hospit
rang
increas
patient
requir
intens
care
unit
icu
care
hospitalacquir
pneumonia
hap
second
common
frequent
fatal
nosocomi
infect
clinic
diagnosi
pneumonia
usual
establish
basi
sign
symptom
chest
radiograph
although
distinguish
cap
hap
condit
congest
heart
failur
pulmonari
embol
chemic
aspir
pneumonia
sometim
difficult
defin
etiolog
agent
also
challeng
although
earli
empir
therapi
necessari
import
identifi
caus
pathogen
patient
requir
hospit
confirm
appropri
therapi
reduc
unnecessari
antimicrobi
use
diagnosi
manag
pneumonia
becom
complex
due
grow
number
age
comorbid
debilit
institution
immunocompromis
individu
divers
array
microorgan
caus
pneumonia
increas
antimicrobi
resist
aspir
oropharyng
nasopharyng
secret
main
mechan
contamin
lower
airway
bacteria
person
awak
glottal
reflex
prevent
aspir
sleep
normal
person
aspir
small
volum
pharyng
secret
oropharyng
secret
may
contain
microorgan
per
millilit
aspir
littl
ml
may
carri
bacteria
oropharynx
healthi
individu
colon
divers
microorgan
vari
potenti
virul
abil
microorgan
colon
oropharynx
caus
lower
respiratori
tract
infect
determin
part
interact
specif
microbi
adhesin
cellular
receptor
exampl
streptococcu
pneumonia
contain
multipl
adhes
bind
receptor
plateletactiv
factor
epitheli
cell
interact
enhanc
cigarett
smoke
infect
respiratori
virus
particul
air
pollut
link
increas
risk
pneumococc
pneumonia
likewis
staphylococcu
aureu
express
multipl
adhesin
bind
host
extracellular
matrix
protein
gramneg
bacteri
pathogen
also
possess
specif
adhesin
mani
form
macromolecular
structur
term
pili
klebsiella
pneumonia
exploit
two
distinct
pili
adher
epitheli
cell
type
pili
bind
divers
host
target
molecul
expos
mannos
residu
type
pili
interact
extracellular
matrix
protein
sever
mechan
airway
prevent
adher
colon
potenti
bacteri
pathogen
dure
perform
respons
pathogen
isol
patient
sever
cap
gramneg
enter
bacilli
aureu
legionella
speci
respiratori
virus
uncommon
caus
cap
although
local
outbreak
markedli
increas
incid
legionella
methicillinresist
staphylococcu
aureu
mrsa
origin
nosocomi
pathogen
appear
commun
refer
communityacquir
mrsa
communityacquir
mrsa
lead
sever
pulmonari
infect
includ
necrot
hemorrhag
pneumonia
pseudomona
aeruginosa
infect
uncommon
absenc
specif
risk
factor
recent
antibiot
treatment
acquir
immunodefici
syndrom
aid
sever
pulmonari
comorbid
especi
bronchiectasi
cystic
fibrosi
sever
chronic
obstruct
pulmonari
diseas
copd
like
etiolog
sever
cap
vari
differ
patient
popul
depend
age
comorbid
includ
hiv
infect
pneumonia
remain
one
major
caus
morbid
children
europ
million
case
childhood
pneumonia
yearli
account
hospit
admiss
children
radiograph
defin
pneumonia
present
febril
ill
infant
month
old
infecti
ill
first
year
life
children
younger
year
pneumonia
respiratori
syncyti
viru
frequent
microorgan
wherea
pneumonia
lead
caus
pneumonia
older
children
young
adult
adult
increas
age
associ
chang
distribut
microbi
caus
increas
respiratori
epitheli
cell
synthes
secret
peptid
term
defensin
cathelicidin
possess
broadspectrum
antimicrobi
activ
distal
airway
alveoli
pulmonari
surfact
protein
c
inhibit
bacteri
bind
host
cell
also
promot
phagocytosi
select
bacteria
presenc
complement
immunoglobulin
particularli
immunoglobulin
iga
also
prevent
colon
oropharynx
addit
protect
provid
host
factor
upper
airway
microbiota
may
modul
suscept
pathogen
indic
evid
broadspectrum
antimicrobi
therapi
predispos
colon
infect
effect
microbiota
oper
competit
bind
site
nutrit
resourc
modul
express
specif
host
defens
molecul
interact
virul
quantiti
aspir
inhal
microorgan
individu
innat
adapt
immun
respons
determin
whether
pneumonia
develop
altern
aspir
bacteria
upper
airway
mycoplasma
pneumonia
chlamydophila
speci
coxiella
burnetii
legionella
mycobacterium
tuberculosi
enter
lower
respiratori
tract
inhal
inhal
pneumonia
often
due
microorgan
surviv
suspend
air
prolong
period
present
droplet
nuclei
smaller
abl
evad
innat
immun
respons
true
incid
cap
uncertain
ill
report
patient
requir
hospit
estim
incid
cap
rang
case
per
person
per
year
substanti
higher
rate
older
adult
although
sever
diseas
influenc
patient
age
presenc
type
coexist
condit
sever
diseas
also
relat
pathogen
pneumonia
pneumonia
chlamydophila
pneumonia
haemophilu
influenza
virus
caus
mild
cap
tabl
wherea
pneumonia
pneumonia
h
influenza
caus
cap
sever
enough
warrant
hospit
tabl
frequent
identifi
pathogen
caus
sever
cap
ie
cap
requir
icu
care
includ
pneumonia
enter
gramneg
bacilli
aureu
legionella
pneumophila
pneumonia
h
influenza
respiratori
virus
tabl
sever
cap
episod
caus
polymicrobi
infect
even
extens
diagnost
proce
geograph
factor
season
time
travel
histori
occup
unusu
exposur
modifi
risk
variou
microbi
etiolog
cap
exampl
increas
frequenc
pneumonia
found
soldier
painter
south
african
gold
miner
burkholderia
pseudomallei
melioidosi
endem
rural
tropic
exposur
pet
bird
work
poultri
especi
turkey
farm
process
plant
increas
risk
psittacosi
chlamydophila
psittaci
contact
hors
larg
mammal
includ
cattl
swine
sheep
goat
deer
increas
exposur
rhodococcu
rodent
contact
suggest
possibl
infect
yersinia
pesti
plagu
rural
southwestern
unit
state
francisella
tularensi
tularemia
rural
arkansa
nantucket
massachusett
exposur
sheep
dog
cat
prompt
evalu
coxiella
burnetii
q
fever
role
season
time
illustr
increas
incid
lower
respiratori
tract
infect
due
pneumonia
h
influenza
winter
month
pneumonia
caus
sever
acut
respiratori
syndrom
sar
due
coronaviru
emerg
epidem
form
southeast
asia
anoth
coronaviru
caus
emerg
middl
east
respiratori
syndrom
mer
final
infecti
agent
caus
anthrax
tularemia
plagu
may
use
bioterror
biowarfar
purpos
caus
lower
respiratori
tract
infect
earlyonset
hap
day
hospit
often
due
microorgan
also
associ
cap
pneumonia
h
influenza
anaerob
lateonset
hap
day
hospit
mainli
caus
mrsa
enter
gramneg
bacilli
p
aeruginosa
nonferment
acinetobact
baumannii
maltophilia
polymicrobi
infect
factor
increas
risk
hap
includ
antibiot
exposur
old
age
sever
comorbid
underli
immunosuppress
colon
oropharynx
virul
microorgan
condit
promot
pulmonari
aspir
inhibit
cough
eg
thoracoabdomin
surgeri
endotrach
intub
insert
nasogastr
tube
supin
posit
exposur
contamin
respiratori
equip
recent
studi
suggest
multidrugresist
microorgan
frequent
earlyonset
hap
initi
thought
risk
factor
earlyonset
pneumonia
reapprais
health
care
reflect
continuum
mani
tradit
inpati
servic
provid
outpati
set
physician
often
categor
new
infect
subject
communityacquir
howev
health
careassoci
infect
uniqu
epidemiolog
like
hospitalacquir
infect
result
health
careacquir
pneumonia
hcap
recogn
separ
entiti
american
thorac
societi
at
infecti
diseas
societi
america
idsa
aureu
frequenc
sever
pneumonia
annual
incid
cap
noninstitution
older
adult
estim
per
compar
per
gener
popul
although
older
adult
particularli
risk
pneumococc
pneumonia
also
increas
rate
pneumonia
due
group
b
streptococci
moraxella
catarrhali
h
influenza
l
pneumophila
gramneg
bacilli
c
pneumonia
polymicrobi
infect
although
absolut
rate
infect
pneumonia
decreas
age
pathogen
account
smaller
proport
pneumonia
older
adult
younger
popul
patient
older
year
higher
incid
aspir
pneumonia
lower
incid
infect
legionella
speci
younger
patient
alcohol
consumpt
import
risk
factor
cap
potenti
impair
level
conscious
thu
increas
risk
aspir
oropharyng
content
addit
divers
effect
alcohol
innat
adapt
immun
report
may
contribut
increas
risk
alcohol
shown
independ
risk
factor
increas
rate
sever
pneumonia
especi
due
pneumonia
predisposit
persist
sever
month
cessat
alcohol
consumpt
smoke
one
import
risk
factor
cap
associ
increas
frequenc
cap
due
pneumonia
l
pneumophila
influenza
smoke
alter
mucociliari
transport
humor
cellular
defens
affect
epitheli
cell
increas
adhes
pneumonia
h
influenza
oropharyng
epithelium
frequent
comorbid
associ
cap
copd
patient
copd
increas
risk
cap
due
alter
mechan
cellular
defens
allow
bacteri
colon
lower
airway
patient
sever
copd
forc
expiratori
volum
second
predict
bronchiectasi
increas
risk
pneumonia
caus
h
influenza
p
aeruginosa
patient
copd
treat
oral
corticosteroid
long
period
risk
infect
aspergillu
speci
increas
pneumonia
remain
major
caus
morbid
mortal
patient
cystic
fibrosi
first
decad
life
aureu
nontyp
h
influenza
common
pathogen
although
p
aeruginosa
occasion
isol
infant
year
age
patient
cystic
fibrosi
harbor
p
aeruginosa
harbor
burkholderia
cepacia
stenotrophomona
maltophilia
achromobact
xylosoxidan
nontubercul
mycobacteria
emerg
pathogen
popul
comorbid
associ
increas
rate
cap
consequ
mortal
includ
congest
heart
failur
chronic
kidney
liver
diseas
cancer
diabet
dementia
cerebrovascular
diseas
immunodefici
eg
neutropenia
lymphoprolif
diseas
immunoglobulin
defici
human
immunodefici
viru
hiv
infect
contrast
syndrom
gradual
onset
fever
nonproduct
cough
rel
normal
white
blood
cell
count
patient
without
readili
demonstr
bacteri
pathogen
call
atyp
pneumonia
frequent
system
complaint
promin
respiratori
one
atyp
syndrom
characterist
infect
pathogen
pneumonia
chlamydophila
speci
c
burnetii
virus
howev
sever
studi
includ
one
includ
patient
mild
cap
treat
outpati
basi
found
neither
clinic
symptom
radiograph
manifest
suffici
sensit
specif
guid
pathogendirect
antibiot
treatment
typic
versu
atyp
microorgan
therefor
current
guidelin
emphas
use
typic
versu
atyp
classif
determin
initi
empir
antibiot
treatment
cap
clinic
find
best
differenti
cap
acut
respiratori
tract
infect
cough
fever
tachypnea
tachycardia
pulmonari
crackl
cap
present
person
five
factor
specif
sign
pulmonari
consolid
present
one
third
case
warrant
hospit
frequent
absent
patient
less
ill
earli
evolut
diseas
pain
cough
may
absent
physic
examin
may
normal
fever
debilit
older
patient
vagu
clinic
manifest
pneumonia
common
presenc
fever
appar
sourc
especi
accompani
confus
tachypnea
justifi
obtain
chest
radiograph
methicillinsensit
methicillinresist
p
aeruginosa
frequent
associ
microorgan
compar
cap
hcap
patient
sever
diseas
higher
mortal
greater
length
hospit
stay
greater
cost
care
pneumonia
character
presenc
fever
alter
gener
wellb
respiratori
symptom
cough
sputum
product
dyspnea
pleurit
pain
hemoptysi
older
immunocompromis
patient
sign
symptom
pulmonari
infect
may
mute
overshadow
nonspecif
complaint
temperatur
greater
c
accompani
chill
never
attribut
bronchiti
without
examin
chest
radiograph
occasion
classic
histori
patient
pneumococc
infect
present
sudden
onset
rigor
follow
pleurit
chest
pain
dyspnea
cough
rusti
sputum
similarli
patient
legionella
pneumonia
may
complain
predominantli
diarrhea
fever
headach
confus
myalgia
pneumonia
infect
extrapulmonari
manifest
myring
enceph
uveiti
iriti
myocard
may
present
howev
rare
clinic
histori
clearli
suggest
specif
etiolog
diagnosi
inform
obtain
clinic
histori
physic
examin
suffici
confirm
diagnosi
pneumonia
definit
diagnosi
requir
find
new
opac
chest
radiograph
older
patient
especi
multipl
comorbid
pneumonia
may
present
gener
weak
decreas
appetit
alter
mental
statu
incontin
decompens
due
underli
diseas
presenc
tachypnea
may
preced
sign
pneumonia
day
tachycardia
anoth
common
initi
sign
less
frequent
specif
tachypnea
fever
absent
older
patient
owe
lack
specif
symptom
diagnosi
cap
frequent
delay
older
adult
older
patient
pneumonia
present
alter
mental
statu
without
fever
delay
receiv
antibiot
hour
arriv
delay
increas
mortal
divis
cap
typic
atyp
syndrom
use
predict
like
pathogen
select
appropri
empir
therapi
clinic
pictur
typic
cap
diseas
characterist
caus
bacteria
pneumonia
h
influenza
k
pneumonia
initi
present
frequent
acut
intens
chill
product
cough
present
sputum
purul
bloodi
pleurit
pain
may
suggest
pneumonia
physic
examin
reveal
typic
find
pulmonari
consolid
see
chapter
blood
test
show
leukocytosi
neutrophilia
presenc
band
form
case
chest
radiographi
show
lobar
consolid
air
bronchogram
fig
clue
etiolog
diagnosi
may
lie
outsid
respiratori
tract
bradycardia
relat
amount
fever
puls
increas
temperatur
elev
associ
pneumonia
due
legionella
c
psittaci
mycoplasma
f
tularensi
pneumonia
infect
may
present
extrapulmonari
manifest
includ
arthralgia
cervic
lymphadenopathi
bullou
myring
diarrhea
myalgia
myocard
hepat
nausea
pericard
vomit
skin
lesion
erythema
multiform
erythema
nodosum
suggest
mycoplasma
infect
well
tuberculosi
endem
fungal
infect
wherea
lesion
ecthyma
gangrenosum
often
seen
p
aeruginosa
infect
final
examin
must
look
presenc
complic
pleural
effus
pericard
endocard
arthriti
central
nervou
system
involv
may
necessit
diagnost
procedur
potenti
chang
therapi
patient
suspect
pneumonia
laboratori
studi
includ
blood
cell
count
serum
glucos
electrolyt
measur
puls
oximetri
arteri
blood
ga
assay
data
provid
basi
make
decis
regard
need
hospit
increas
incid
cap
hivinfect
individu
provid
addit
rational
hiv
test
particularli
patient
risk
factor
cap
mark
leukocytosi
leftward
shift
often
encount
infect
caus
pneumonia
h
influenza
gramneg
bacilli
pneumonia
chlamydophila
speci
coxiella
nonbacteri
caus
pneumonia
leukopenia
may
seen
overwhelm
pneumococc
gramneg
bacillari
pneumonia
serum
level
creactiv
protein
erythrocyt
sediment
rate
increas
higher
valu
bacteri
viral
pneumonia
thrombocytopenia
thrombocytosi
associ
greater
sever
pneumonia
higher
mortal
procalcitonin
pct
precursor
calcitonin
present
increas
concentr
blood
person
bacteri
infect
pct
assay
use
evalu
sever
prognosi
evolut
pneumonia
importantli
procalcitonin
use
deescal
antibiot
stop
antibiot
level
decreas
certain
cutoff
point
random
trial
pctguid
strategi
compar
guidelinebas
algorithm
reveal
equival
primari
outcom
treatment
lower
respiratori
tract
infect
pctguid
strategi
result
reduc
antibiot
exposur
durat
fewer
advers
effect
antibiot
treatment
shorter
length
stay
radiograph
evalu
necessari
establish
presenc
pneumonia
combin
histor
data
physic
find
laboratori
result
reliabl
confirm
diagnosi
limit
chest
radiographi
includ
interobserv
variabl
suboptim
specif
particularli
patient
acut
respiratori
distress
syndrom
ard
convers
sensit
chest
radiograph
decreas
patient
emphysema
bulla
structur
abnorm
lung
may
present
delay
subtl
radiograph
chang
obes
patient
may
difficult
discern
exist
pneumonia
patient
earli
infect
sever
dehydr
profound
granulocytopenia
comput
tomographi
ct
chest
provid
sensit
mean
detect
minor
radiograph
abnorm
howev
chest
ct
recommend
patient
suspect
pneumonia
appar
normal
chest
radiograph
although
sever
radiograph
pattern
associ
pneumonia
caus
specif
microorgan
presenc
certain
pattern
reliabl
method
diagnos
specif
pathogen
nonetheless
presenc
air
bronchogram
lobar
efig
segment
pattern
characterist
typic
atyp
caus
pneumonia
contrast
mix
pattern
alveolar
interstiti
diseas
efig
frequent
observ
atyp
pneumonia
pneumonia
complic
aspir
frequent
anaerob
efig
often
involv
superior
segment
right
lower
lobe
posterior
segment
right
upper
lobe
well
correspond
segment
left
infect
develop
hematogen
seed
often
appear
multipl
round
small
opac
sometim
caviti
basal
predomin
distribut
blood
flow
greatest
demonstr
lung
abscess
efig
cavit
necrot
pneumonia
suggest
infect
anaerob
aureu
streptococcu
pyogen
gramneg
bacilli
pleural
effus
frequent
accompani
pneumonia
size
pleural
effus
chest
radiograph
help
determin
whether
thoracentesi
perform
identif
infect
microorgan
facilit
use
specif
therapi
instead
unnecessarili
broadspectrum
antimicrobi
agent
although
util
sputum
examin
debat
see
later
pleural
fluid
present
two
set
blood
cultur
obtain
patient
hospit
cap
optim
cultur
result
requir
specimen
obtain
initi
antimicrobi
therapi
sputum
sampl
must
care
collect
transport
process
order
optim
recoveri
common
bacteri
pathogen
recommend
summar
tabl
microscop
examin
expector
sputum
easiest
rapidli
avail
method
evalu
microbiolog
lower
respiratori
tract
infect
valid
expector
sputum
specimen
obtain
patient
hospit
cap
interpret
sputum
cultur
crucial
ensur
oropharyng
content
unduli
contamin
specimen
presenc
squamou
epitheli
cell
per
lowpow
field
magnif
indic
excess
oropharyng
contamin
specimen
discard
repres
pulmonari
milieu
specimen
squamou
cell
men
corrobor
presenc
bacteria
good
qualiti
gramstain
sputum
presenc
singl
preponder
morphotyp
bacteria
consid
diagnost
absenc
inform
gram
stain
predict
valu
sputum
cultur
low
latest
idsaat
guidelin
recommend
obtain
sputum
sampl
gram
stain
cultur
hospit
patient
clinic
indic
list
tabl
option
patient
without
condit
patient
hap
ventilatorassoci
pneumonia
vap
rang
potenti
pathogen
broad
antimicrobi
suscept
pattern
divers
vigor
diagnost
measur
justifi
ventil
patient
equival
sputum
endotrach
aspir
criteria
valid
sputum
although
gram
stain
qualit
cultur
endotrach
aspir
excel
sensit
poor
specif
quantit
cultur
endotrach
aspir
sampl
may
help
distinguish
colon
infect
howev
difficulti
choos
quantit
threshold
vap
chosen
consid
rang
quantit
cultur
cfuml
rather
singl
cutoff
bacteri
agent
pneumonia
cultiv
convent
laboratori
media
exampl
legionella
requir
buffer
charcoal
yeast
extract
agar
isol
wherea
recoveri
chlamydophila
speci
c
burnetii
requir
cultur
mammalian
cell
line
necessari
specimen
sent
special
refer
laboratori
appropri
procedur
cultur
certain
agent
bacteri
pneumonia
pose
major
health
risk
laboratori
worker
eg
f
tularensi
bacillu
anthraci
c
burnetii
specimen
suspect
harbor
one
agent
dealt
care
biolog
safeti
hood
isol
pathogen
reserv
special
laboratori
although
overal
yield
blood
cultur
less
patient
hospit
cap
posit
cultur
blood
pleural
fluid
establish
etiolog
diagnosi
pneumonia
surprisingli
detect
rate
bacteremia
lower
patient
mild
cap
higher
patient
mani
polymorphonuclear
white
blood
cell
cell
lowpow
field
sampl
patient
granulocytopen
ideal
see
fig
gramstain
expector
sputum
specimen
accept
qualiti
care
examin
use
magnif
oil
immers
object
specif
fluoresc
antibodi
use
evalu
sputum
respiratori
tract
specimen
presenc
legionella
select
pathogen
see
chapter
accept
sputum
obtain
specif
gram
stain
pneumococc
pneumonia
estim
greater
fastidi
natur
pneumonia
h
influenza
lead
death
organ
sensit
sputum
cultur
may
lower
sputum
gram
stain
examin
pneumonia
h
influenza
contrast
aureu
gramneg
bacilli
may
domin
even
caus
patient
ill
bacteria
hardier
may
prolifer
sampl
transport
process
true
pneumonia
due
aureu
gramneg
bacilli
doubt
gram
stain
valid
sputum
speci
gram
stain
cultur
endotrach
aspir
bronchoscop
obtain
specimen
use
protect
specimen
brush
bal
procedur
hospit
patient
gram
stain
cultur
strongli
consid
patient
risk
factor
infect
antimicrobialresist
organ
unusu
pathogen
bal
bronchoalveolar
lavag
icu
intens
care
unit
consid
gold
standard
realtim
multiplex
polymeras
chain
reaction
assay
detect
respiratori
virus
immunocompet
immunosuppress
host
see
chapter
detail
inform
nucleic
acid
amplif
test
respiratori
pathogen
develop
nucleic
acid
amplif
test
serolog
techniqu
use
establish
microbiolog
diagnosi
pneumonia
caus
pathogen
readili
cultur
exampl
includ
common
pathogen
pneumonia
c
pneumonia
l
pneumophila
less
common
caus
pneumonia
caus
agent
tularemia
brucellosi
psittacosi
certain
virus
diagnosi
usual
requir
convalesc
specimen
demonstr
fourfold
increas
immunoglobulin
ig
g
titer
present
acut
specimen
test
help
initi
patient
manag
util
defin
epidemiolog
pertin
infecti
agent
igm
antibodi
appear
earlier
igg
antibodi
detect
pathogenspecif
igm
serum
use
earli
serolog
diagnosi
certain
acut
infect
problem
encount
use
expector
sputum
may
necessari
perform
invas
procedur
obtain
suitabl
materi
microscopi
cultur
may
import
manag
patient
lifethreaten
cap
diagnost
materi
otherwis
obtain
patient
progress
pneumonia
despit
seemingli
appropri
antimicrobi
therapi
immunocompromis
patient
patient
hap
especi
set
endotrach
intub
although
qualit
cultur
materi
obtain
endotrach
suction
excel
sensit
specif
cultur
poor
thu
overreli
cultur
lead
antibiot
overtreat
reliabl
bronchoscop
procedur
determin
microbi
etiolog
pneumonia
depend
techniqu
use
organ
sought
compar
sputum
cultur
optim
process
bronchoscop
specimen
demonstr
improv
sensit
equal
specif
cultur
pathogen
fungi
mycobacteria
howev
materi
unaccept
poor
specif
routin
bacteri
cultur
owe
oropharyng
contamin
semiquantit
quantit
cultur
materi
obtain
bronchoscop
protect
sheath
brush
bronchoalveolar
lavag
bal
direct
lung
aspir
success
use
aerob
anaerob
bacteri
cultur
see
chapter
protect
sheath
brush
cultur
threshold
colonyform
unit
cfu
ml
recommend
distinguish
colon
infect
howev
duplic
sampl
yield
dispar
quantit
result
bal
fluid
quantit
cultur
bacteria
qualit
cultur
fungi
mycobacteria
virus
concentr
stain
cytochem
sever
cap
especi
warrant
icu
care
prior
antibiot
treatment
decreas
yield
blood
cultur
latest
idsaat
guidelin
recommend
obtain
blood
sampl
cultur
hospit
patient
clinic
indic
list
tabl
option
patient
without
condit
cap
case
pleural
effus
may
present
although
specif
pleural
exud
cultur
high
sensit
low
low
incid
invas
pleura
diagnost
thoracentesi
perform
signific
pleural
effus
present
gram
stain
pleural
fluid
may
produc
indic
infect
organ
within
hour
cultur
identif
may
requir
hour
commerci
assay
use
detect
capsular
polysaccharid
antigen
pneumonia
l
pneumophila
serogroup
urin
requir
less
hour
sensit
test
littl
affect
prior
antibiot
treatment
inde
result
may
remain
posit
sever
week
success
treatment
l
pneumophila
serogroup
sensit
specif
greater
urinari
antigen
test
current
help
rapid
test
diagnosi
legionella
infect
major
limit
urinari
antigen
test
current
avail
test
intend
detect
l
pneumophila
serogroup
antigen
although
common
caus
legionella
infect
sensit
pneumonia
urinari
antigen
detect
specif
degre
posit
pneumonia
urinari
antigen
test
correl
pneumonia
sever
index
psi
pneumonia
antigen
test
may
also
appli
pleural
fluid
sensit
specif
almost
urin
specimen
children
frequent
carrier
pneumonia
nasopharynx
may
test
posit
absenc
evid
pneumonia
test
therefor
interpret
caution
children
recent
idsa
at
guidelin
recommend
pneumonia
l
pneumophila
urinari
antigen
detect
hospit
patient
clinic
indic
list
tabl
option
patient
without
condit
antigen
mani
common
respiratori
virus
influenza
viru
respiratori
syncyti
viru
adenoviru
parainfluenza
virus
detect
direct
immunofluoresc
enzymelink
immunoassay
rapid
antigen
detect
test
influenza
provid
etiolog
diagnosi
within
minut
test
perform
vari
accord
test
use
viral
strain
sampl
type
durat
ill
patient
age
show
sensit
rang
specif
approach
adult
see
chapter
cultur
procedur
virus
fastidi
bacteria
pneumonia
c
pneumonia
l
pneumophila
bordetella
pertussi
normal
colon
human
respiratori
tract
insensit
slow
help
guid
therapi
pathogen
detect
nucleic
acid
amplif
test
sensit
gener
superior
tradit
procedur
facilit
decis
second
key
initi
decis
select
initi
antimicrobi
therapi
psi
etabl
score
system
deriv
retrospect
analysi
cohort
patient
cap
prospect
valid
separ
cohort
patient
cap
psi
heavili
weight
age
mean
less
use
extrem
age
valid
children
outpati
treatment
recommend
patient
psi
score
less
class
ii
patient
psi
score
class
iii
may
benefit
brief
hospit
inpati
care
appropri
patient
score
greater
class
iv
v
prospect
studi
commun
teach
hospit
demonstr
hospit
admiss
decis
base
psi
may
safe
effect
appli
clinic
practic
psi
complex
often
need
decis
support
tool
effici
use
busi
emerg
depart
british
thorac
societi
valid
simpler
score
admiss
triag
decis
algorithm
assign
point
follow
find
present
confus
urea
higher
mmoll
equal
bun
mgdl
respiratori
rate
low
systol
mm
hg
diastol
mm
hg
blood
pressur
age
year
older
outpati
treatment
recommend
point
brief
inpati
supervis
outpati
care
recommend
point
hospit
recommend
greater
consider
icu
care
patient
score
risk
stratif
psi
base
associ
mortal
therefor
sensit
logist
social
issu
reliabl
oral
intak
includ
antibiot
home
support
patient
initi
admit
gener
floor
subsequ
transfer
icu
higher
mortal
patient
equival
sever
ill
admit
directli
icu
neither
psi
accur
determin
need
icu
care
patient
without
obviou
indic
need
mechan
ventil
vasopressor
support
still
emerg
depart
sever
score
develop
critic
decis
score
share
mani
common
risk
factor
tabl
appear
equal
effect
manag
sever
cap
per
guidelin
associ
decreas
mortal
optim
use
score
identifi
atrisk
patient
need
addit
evalu
monitor
even
initi
admit
icu
whenev
possibl
treatment
pneumonia
use
antibiot
narrowest
spectrum
possibl
select
basi
underli
pathogen
howev
pathogen
rare
identifi
time
present
especi
pneumonia
manag
outpati
set
optim
outcom
associ
rapid
initi
antibiot
initi
treatment
patient
fluoresc
evalu
one
studi
threshold
cfuml
diagnos
bacteri
pneumonia
correl
well
diagnos
base
protect
sheath
brush
result
histolog
examin
lung
bal
permit
identif
contamin
specimen
ie
greater
squamou
epitheli
cell
immedi
diagnosi
infect
ie
intracellular
bacteria
examin
polymorphonuclear
leukocyt
exclus
infect
ie
absenc
bacteri
pathogen
cultur
bal
fluid
although
sensit
reduc
prior
antibiot
administr
one
studi
use
quantit
cultur
obtain
protect
sheath
brush
bal
compar
qualit
cultur
endotrach
aspir
clinic
evalu
associ
lower
mortal
rate
earlier
revers
organ
dysfunct
less
antibiot
use
howev
random
trial
use
quantit
cultur
protect
sheath
brush
bal
specimen
rather
quantit
cultur
endotrach
aspir
patient
vap
replic
find
use
sophist
algorithm
ie
clinic
pulmonari
infect
score
increas
diagnost
accuraci
clinic
judgment
transthorac
lung
aspir
obtain
specimen
suitabl
microbiolog
cytolog
examin
directli
lung
parenchyma
efig
wide
use
diagnos
malign
pulmonari
lesion
infecti
diseas
immunocompet
host
diagnost
yield
transthorac
lung
aspir
approxim
seriou
complic
transthorac
lung
aspir
includ
pneumothorax
hemoptysi
even
smallgaug
needl
use
sever
diseas
may
present
fever
chest
radiograph
opac
mimic
cap
etabl
diseas
suspect
radiograph
resolut
unusu
quick
lack
respons
initi
subsequ
antibiot
treatment
patient
hap
particularli
vap
classic
sign
symptom
pneumonia
includ
new
radiograph
chang
fever
leukocytosi
leukopenia
purul
pulmonari
secret
neither
suffici
sensit
specif
confirm
presenc
pulmonari
infect
atelectasi
pulmonari
hemorrhag
ard
pulmonari
embol
among
other
condit
may
mimic
pneumonia
patient
suspect
hap
vap
microbiolog
confirm
pneumonia
import
order
avoid
unnecessari
treatment
increas
antibiot
resist
diagnosi
pneumonia
made
clinician
must
decid
appropri
treatment
set
outpati
gener
hospit
bed
icu
appli
predict
rule
patient
clinic
featur
common
atyp
pathogen
import
recogn
cap
treatment
guidelin
base
broad
epidemiolog
consider
may
vari
locat
variat
regimen
base
specif
epidemiolog
clinic
characterist
strongli
suggest
one
less
common
cap
pathogen
mix
aerobicanaerob
flora
due
aspir
presenc
gramneg
enterobacteriacea
p
aeruginosa
patient
specifi
risk
factor
tuberculosi
possibl
fluoroquinolon
use
cautious
cap
littl
day
fluoroquinolon
administr
suffici
select
fluoroquinoloneresist
tuberculosi
greatest
factor
consid
choic
regimen
histori
recent
use
agent
widespread
fluoroquinolon
use
especi
subtherapeut
dose
use
ciprofloxacin
associ
fluoroquinolon
resist
pneumonia
isol
hong
kong
fluoroquinolon
resist
subsequ
treatment
failur
report
pneumococc
cap
less
common
use
fluoroquinolon
improv
activ
respiratori
pathogen
contrast
frequenc
macrolid
resist
pneumonia
increas
macrolid
use
monotherapi
pneumonia
infect
unless
vitro
test
confirm
patient
strain
suscept
macrolid
empir
antibiot
treatment
sever
cap
scap
remain
controversi
predominantli
due
lack
treatment
studi
specif
focus
scap
spectrum
etiolog
clearli
greater
scap
even
penicillinsensit
pneumococci
still
like
etiolog
whether
scap
justifi
aggress
diagnost
test
broader
spectrum
empir
treatment
case
establish
retrospect
studi
suggest
combin
therapi
specif
sever
pneumococc
pneumonia
scap
gener
associ
lower
mortal
larg
cohort
older
patient
cap
need
hospit
antibiot
treatment
includ
azithromycin
associ
lower
risk
mortal
compar
antibiot
empir
therapi
vap
necessarili
broad
rang
potenti
pathogen
larg
mortal
increas
respons
pathogen
resist
initi
empir
antibiot
regimen
tabl
recommend
empir
regimen
includ
expandedspectrum
agent
usual
combin
aminoglycosid
mrsa
coverag
empir
base
antibiot
sensit
pattern
common
gramneg
pathogen
relev
institut
specif
unit
empir
antibiot
hap
less
well
studi
hap
nonintub
patient
mixtur
cap
pathogen
pathogen
found
vap
although
frequenc
latter
like
lower
especi
case
present
earli
admiss
greatest
risk
mdr
pathogen
nonintub
patient
hap
recent
antibiot
therapi
monotherapi
probabl
adequ
patient
pneumonia
must
empir
select
initi
empir
antimicrobi
therapi
physician
consid
set
pneumonia
aros
eg
commun
hospit
nurs
home
sever
ill
age
patient
presenc
comorbid
immunosuppress
recent
antimicrobi
therapi
specif
clinic
manifest
ill
geograph
facilityspecif
factor
local
preval
specif
microorgan
eg
c
burnetii
l
pneumophila
endem
mycos
multidrugresist
mdr
pathogen
may
also
affect
initi
treatment
choic
hospit
patient
specimen
cultur
blood
sputum
pleural
fluid
present
obtain
treatment
brief
delay
start
therapi
perform
diagnost
procedur
reason
patient
hypotens
howev
delay
hour
may
increas
length
hospit
associ
increas
mortal
standard
therapi
inpati
empir
antibiot
coverag
cap
one
two
regimen
combin
secondor
thirdgener
cephalosporin
combin
macrolid
one
fluoroquinolon
efficaci
respiratori
pathogen
levofloxacin
moxifloxacin
gatifloxacin
either
therapi
effect
penicillinresist
pneumonia
north
american
guidelin
recommend
empir
regimen
cap
activ
atyp
pathogen
pneumonia
c
pneumonia
l
pneumophila
retrospect
analys
patient
hospit
cap
indic
regimen
cover
atyp
pathogen
follow
recommend
made
at
idsa
associ
improv
clinic
outcom
contrast
northern
european
guidelin
suggest
atyp
coverag
need
unless
modifi
factor
advanc
macrolid
doxycyclin
comorbid
fluoroquinolon
advanc
macrolid
antibiot
within
month
fluoroquinolon
alon
advanc
macrolid
suspect
aspir
clindamycin
amoxicillinclavulan
influenza
bacteri
superinfect
fluoroquinolon
nurs
home
patient
fluoroquinolon
alon
amoxicillinclavulan
advanc
macrolid
primari
macrolid
doxycyclin
cefuroxim
amoxicillin
amoxicillinclavulan
altern
fluoroquinolon
modifi
factor
macrolid
doxycyclin
copd
advanc
macrolid
doxycyclin
copd
plu
recent
antibiot
steroid
fluoroquinolon
alon
amoxicillinclavulan
macrolid
secondgener
cephalosporin
macrolid
suspect
aspir
amoxicillinclavulan
macrolid
fluoroquinolon
clindamycin
metronidazol
nurs
home
patient
fluoroquinolon
alon
macrolid
plu
amoxicillinclavulan
secondgener
cephalosporin
american
thorac
societi
comorbid
modifi
factor
includ
cardiopulmonari
diseas
age
older
year
receipt
antimicrobi
within
prior
month
alcohol
prior
immunosuppress
therapi
multipl
medic
comorbid
exposur
child
daycar
center
resid
nurs
home
underli
cardiopulmonari
diseas
multipl
comorbid
recent
antimicrobi
therapi
infecti
diseas
societi
america
comorbid
includ
copd
diabet
renal
congest
heart
failur
malign
advanc
macrolid
azithromycin
clarithromycin
telithromycin
similar
antimicrobi
activ
associ
higher
risk
toxic
indic
limit
secondchoic
agent
highdos
amoxicillin
gday
highdos
amoxicillinclavulan
g
amoxicillin
plu
mg
clavulan
acid
everi
hr
cefpodoxim
cefprozil
cefuroxim
increas
macrolid
resist
erythromycin
reli
upon
ensur
coverag
haemophilu
influenza
combin
inhibitor
prefer
american
thorac
societi
risk
factor
pseudomona
aeruginosa
structur
lung
diseas
ie
bronchiectasi
cystic
fibrosi
corticosteroid
use
mg
prednisoneday
broadspectrum
antibiot
therapi
day
past
month
malnutrit
infecti
diseas
societi
american
risk
factor
p
aeruginosa
includ
structur
lung
diseas
recent
complet
cours
antibiot
steroid
canadian
risk
factor
includ
structur
lung
diseas
recent
antibiot
therapi
recent
hospit
intens
care
unit
antipseudomon
includ
ceftazidim
cefepim
imipenem
meropenem
mezlocillin
piperacillin
piperacillintazobactam
carbapenem
llactamas
inhibitor
cefepim
plu
amikacin
fluoroquinolon
sever
hap
high
risk
recent
abdomin
surgeri
wit
aspir
anaerob
per
tabl
site
infect
mrsa
prior
use
antistaphylococc
antibiot
mrsa
per
tabl
prolong
icu
stay
prior
use
broadspectrum
antibiot
structur
lung
diseas
cystic
fibrosi
bronchiectasi
per
tabl
endem
within
facil
either
impair
cellmedi
immun
failur
respond
antibiot
per
tabl
highrisk
criteria
includ
age
older
year
pancreat
chronic
obstruct
pulmonari
diseas
central
nervou
system
dysfunct
stroke
drug
overdos
coma
statu
epilepticu
congest
heart
failur
malnutrit
diabet
mellitu
endotrach
intub
renal
failur
complic
thoracoabdomin
surgeri
alcohol
patient
consid
low
risk
protocol
address
treatment
neutropen
hivinfect
person
sever
pneumonia
requir
care
icu
character
rapid
radiograph
progress
multilobar
diseas
cavit
case
nosocomi
pneumonia
consid
mild
moder
antimicrobi
treatment
also
suffici
cover
core
pathogen
ticarcillinclavulan
piperacillintazobactam
prefer
inhibitor
treatment
nosocomi
pneumonia
ampicillinsulbactam
lack
adequ
activ
mani
nosocomi
enter
gramneg
bacilli
without
recent
antibiot
exposur
anaerob
appear
play
slightli
greater
role
hap
vap
risk
macroaspir
specif
anaerob
coverag
necessari
appropri
use
unless
legionella
known
endem
institut
target
therapi
pathogen
seldom
necessari
empir
treatment
hap
effort
identifi
caus
infect
especi
crucial
patient
hap
vap
allow
select
optim
antimicrobi
therapi
minim
durat
empir
broadspectrum
coverag
optim
approach
empir
coverag
hcap
remain
controversi
due
variat
health
care
system
definit
pneumonia
nurs
home
chronic
care
facil
resid
seen
bimod
pattern
ambulatori
patient
abl
take
care
activ
daili
live
diseas
resembl
cap
contrast
sever
debilit
patient
tracheostomi
feed
tube
frequent
recent
acut
care
hospit
admiss
frequent
exposur
antibiot
high
risk
mdr
pathogen
treat
vap
regimen
cultureneg
hcap
patient
equival
better
outcom
treat
cap
antibiot
broader
spectrum
treatment
difficult
identifi
admiss
start
broader
therapi
deescal
cap
therapi
cultur
result
return
neg
appear
safe
initi
present
varieti
infecti
pulmonari
syndrom
may
readili
differenti
acut
bacteri
pneumonia
exampl
includ
influenza
sever
acut
respiratori
syndrom
hantaviru
pulmonari
syndrom
viral
pneumonia
milder
case
viral
pneumonia
may
distinguish
low
pct
level
antibiot
safe
withheld
withdrawn
patient
concern
potenti
bioterror
biowarfar
requir
attent
epidemiolog
clinic
microbiolog
signific
pneumonia
due
b
anthraci
anthrax
f
tularensi
tularemia
pesti
plagu
infecti
agent
individu
discuss
later
use
conjug
pneumococc
vaccin
markedli
decreas
invas
pneumococc
infect
children
secondari
reduct
adult
latter
effect
probabl
repres
interrupt
transmiss
aerosol
droplet
direct
physic
contact
conjug
vaccin
effect
block
colon
howev
widespread
use
conjug
vaccin
unit
state
result
increas
number
proport
case
invas
pneumococc
diseas
due
isol
polysaccharid
capsul
type
includ
sevenval
vaccin
consequ
conjug
vaccin
contain
capsular
polysaccharid
antigen
develop
approv
us
food
drug
administr
classic
present
pneumococc
pneumonia
consist
singl
rigor
follow
sustain
fever
cough
dyspnea
product
rusti
mucoid
sputum
gross
hemoptysi
unusu
sever
pleurit
chest
pain
common
radiograph
appear
pneumococc
pneumonia
often
either
lobar
consolid
see
fig
efig
patchi
bronchopneumonia
efig
although
pneumococci
caus
necrot
pneumonia
cavit
rare
develop
small
parapneumon
effus
frequent
found
progress
frank
empyema
neutropenia
may
develop
patient
overwhelm
infect
although
gram
stain
purul
sputum
reveal
numer
characterist
lancetshap
diplococci
blunt
end
commonli
seen
pair
short
chain
absenc
predomin
flora
strongli
suggest
pneumococc
pneumonia
fig
good
qualiti
sputum
specimen
alway
obtain
organ
recov
sputum
cultur
fewer
half
case
even
singl
dose
antibiot
affect
yield
sputum
cultur
contribut
discrep
sputum
gram
stain
cultur
result
frequenc
posit
blood
cultur
fallen
hospit
patient
less
mani
contemporari
seri
decreas
may
reflect
greater
percentag
blood
cultur
drawn
antibiot
emphasi
time
antibiot
dose
emerg
depart
deemphasi
blood
cultur
cap
gener
andor
benefit
vaccin
invas
pneumococc
diseas
rapid
urinari
antigen
pneumonia
test
offer
altern
approach
diagnosi
pneumococc
cap
becom
wide
use
diagnosi
narrow
antibiot
therapi
despit
satisfactori
sensit
specif
urinari
antigen
test
complementari
cultur
method
sinc
provid
inform
antimicrobi
suscept
infect
organ
appropri
antibiot
clinic
respons
usual
expect
within
hour
onset
suppur
complic
purul
pericard
mening
endocard
arthriti
cellul
initi
chapter
inform
may
obtain
organ
center
diseas
control
prevent
wwwcdcgov
idsa
wwwidsocietyorg
world
health
organ
wwwwhoorg
see
chapter
etiolog
agent
patient
pneumonia
identifi
initi
antimicrobi
regimen
adjust
base
result
vitro
suscept
test
ideal
drug
known
pathogen
narrowest
spectrum
activ
efficaci
least
toxic
least
costli
pathogenbas
modif
therapi
particularli
import
hap
prolong
use
broadspectrum
empir
agent
promot
emerg
mdr
pathogen
recommend
specif
drug
choic
specif
microorgan
discuss
section
devot
individu
microorgan
summar
tabl
pathogen
identifi
reevalu
initi
therapeut
regimen
must
take
account
patient
respons
therapi
chang
parenter
oral
antimicrobi
therapi
safe
made
hospit
cap
patient
clinic
stabl
abl
absorb
effect
oral
antimicrobi
often
achiev
within
day
inhospit
observ
switch
intraven
oral
antibiot
cap
patient
need
hap
pathogen
frequent
resist
avail
oral
antimicrobi
enter
absorpt
less
predict
sever
ill
greater
initi
oral
antimicrobi
therapi
much
less
frequent
appropri
individu
pneumonia
pathogen
may
uniqu
epidemiolog
diagnost
test
andor
treatment
section
follow
emphas
uniqu
aspect
select
pathogen
group
pneumonia
frequent
caus
cap
among
patient
requir
hospit
overal
incid
pneumococc
pneumonia
approxim
case
per
person
per
year
case
per
case
bacteremia
infect
account
death
annual
unit
state
death
young
elderli
risk
factor
particularli
adult
includ
cigarett
smoke
hiv
infect
even
preserv
count
heavi
alcohol
use
chronic
liver
diseas
genet
defect
host
immun
malnutrit
pneumococc
infect
present
predominantli
winter
earli
spring
often
associ
prior
infect
influenza
respiratori
syncyti
viru
therapi
uncommon
modern
era
except
empyema
appear
increas
due
serotyp
replac
vaccin
popul
serotyp
often
associ
empyema
pneumococc
pneumonia
remain
caus
septic
shock
ard
antimicrobi
resist
complic
treatment
pneumonia
much
world
includ
unit
state
nonmening
isol
pneumonia
redefinit
full
suscept
minimum
inhibitori
smaller
percentag
adult
carriag
rate
increas
greatli
epidem
crowd
condit
unit
state
incid
pneumonia
due
pyogen
per
person
per
year
may
high
per
children
organ
easili
transfer
contact
lead
epidem
group
streptococc
pneumonia
militari
recruit
nurs
home
crowd
set
pneumonia
due
pyogen
often
manifest
late
winter
spring
month
may
follow
episod
influenza
measl
varicella
associ
increas
age
alcohol
abus
diabet
mellitu
cancer
hiv
infect
pyogen
caus
necrot
pneumonia
associ
pleural
empyema
group
b
ie
streptococcu
agalactia
streptococci
major
caus
neonat
sepsi
pneumonia
adult
pneumonia
account
approxim
adult
infect
group
b
streptococci
adult
group
b
streptococc
pneumonia
debilit
develop
pneumonia
consequ
aspir
diabet
cirrhosi
stroke
decubitu
ulcer
neurogen
bladder
also
risk
factor
streptococcu
milleri
group
c
streptococci
includ
intermediu
anginosu
constellatu
emerg
signific
respiratori
pathogen
predominantli
caus
empyema
efig
video
lung
abscess
well
superinfect
pneumonia
sever
viral
pneumonia
infect
bacteria
group
share
mani
featur
anaerob
infect
includ
increas
risk
periodont
diseas
alcohol
viridan
microaerophil
streptococci
nonpneumococc
rare
sole
pathogen
patient
pneumonia
commonli
found
mix
facult
anaerob
organ
aspir
pneumonia
cap
pathogen
clinic
indistinguish
pneumococc
pneumonia
exud
pharyng
may
evid
unilobar
involv
common
group
streptococc
pneumonia
pleural
effus
group
streptococc
pneumonia
frequent
may
larg
accumul
rapidli
appear
earli
cours
diseas
particularli
children
pneumonia
caus
streptococci
usual
less
abrupt
milder
pleural
effus
uncommon
lung
tissu
necrosi
rare
despit
frequent
bacteremia
milleri
infect
predominantli
associ
empyema
without
concomit
pneumonia
pneumothorax
time
initi
present
appear
common
milleri
streptococc
empyema
streptococci
common
oropharynx
document
infect
organ
requir
isol
cultur
blood
pleural
fluid
respiratori
specimen
obtain
mean
invas
procedur
fig
pleural
fluid
cultur
children
pyogen
pneumonia
frequent
posit
polymeras
chain
reaction
technolog
hold
promis
aid
diagnosi
especi
group
streptococc
infect
milleri
empyema
concentr
mic
penicillin
less
equal
highlevel
resist
mic
greater
equal
markedli
chang
incid
penicillin
resist
redefinit
driven
discord
previou
lower
mic
breakpoint
clinic
success
rate
rate
increas
frequenc
penicillin
resist
may
stabil
possibl
consequ
pneumococc
conjug
vaccin
shift
outpati
antibiot
prescript
pattern
away
penicillin
resist
pneumonia
due
alter
penicillinbind
protein
rather
product
unlik
cefotaxim
ceftriaxon
cefepim
retain
activ
nonmening
isol
pneumonia
pneumonia
resist
rate
antimicrobi
high
trimethoprimsulfamethoxazol
tmpsmx
tetracyclin
macrolid
clindamycin
rate
higher
among
penicillinresist
pneumococci
highlevel
macrolid
resist
mic
associ
mlsb
macrolid
lincosamid
streptogramin
b
phenotyp
common
europ
associ
vitro
resist
clindamycin
pneumonia
resist
fluoroquinolon
also
emerg
associ
clinic
treatment
failur
recent
exposur
antibiot
increas
likelihood
patient
pneumococc
isol
resist
antibiot
class
antibiot
thu
import
avoid
antibiot
use
prior
day
select
regimen
empir
treatment
pneumococc
infect
retrospect
prospect
observ
studi
suggest
benefit
treat
sever
ill
patient
proven
pneumococc
infect
macrolid
explan
propos
explain
result
includ
nonbactericid
effect
inhibit
biofilm
product
antiinflammatori
effect
macrolid
pyogen
group
streptococcu
found
oropharynx
children
hospit
chronic
lung
diseas
malign
hiv
infect
alcohol
among
common
predispos
condit
haemophilu
pneumonia
activ
smoke
appear
particularli
increas
risk
h
influenza
pneumonia
pneumonia
vaccin
h
influenza
type
b
significantli
chang
epidemiolog
childhood
pneumonia
vaccin
children
still
suscept
unencapsul
nontyp
strain
incid
h
influenza
pneumonia
fallen
dramat
nonbacterem
infect
unencapsul
nontyp
b
strain
common
form
h
influenza
pneumonia
adult
haemophilu
pneumonia
clinic
indistinguish
bacteri
pneumonia
efig
radiograph
haemophilu
pneumonia
may
multilobar
patchi
bronchopneumonia
area
frank
consolid
spheric
radiograph
opac
socal
round
pneumonia
describ
cavit
uncommon
small
parapneumon
effus
may
occasion
progress
empyema
bacteremia
common
children
adult
diagnos
h
influenza
pneumonia
gram
stain
sputum
difficult
small
pleomorph
coccobacilli
often
overlook
cultur
expector
sputum
reveal
h
influenza
half
welldocu
case
pneumonia
asymptomat
colon
nontyp
strain
patient
copd
complic
analysi
gram
stain
sputum
cultur
fig
overal
mortal
rate
h
influenza
pneumonia
higher
patient
bacteremia
extrapulmonari
diseas
associ
foci
infect
empyema
mening
arthriti
pericard
epiglott
common
encapsul
type
b
h
influenza
h
influenza
isol
produc
case
therefor
resist
ampicillin
increas
empyema
andor
pericard
seen
patient
group
streptococc
pneumonia
complic
includ
pneumothorax
mediastin
bronchopleur
fistula
format
classic
nonsuppur
complic
follow
pyogen
pneumonia
glomerulonephr
streptococci
suscept
penicillin
g
ampicillin
mani
cephalosporin
although
streptococci
may
requir
high
dosag
due
phenomenon
toler
growth
inhibit
without
kill
low
intermedi
drug
concentr
resist
clindamycin
erythromycin
found
isol
suscept
test
advis
monotherapi
macrolid
clindamycin
empyema
caus
pathogen
drainag
empyema
fluid
import
compon
therapi
invas
infect
especi
pneumonia
due
h
influenza
estim
account
approxim
case
per
adult
per
year
unit
state
one
common
caus
pneumonia
adult
requir
obtain
sputum
gener
display
moder
number
polymorphonuclear
leukocyt
without
predomin
organ
recoveri
pneumonia
cultur
clinic
specimen
requir
special
media
take
approxim
day
although
acut
mycoplasma
pneumonia
may
stimul
cold
agglutinin
product
titer
greater
nonspecif
result
also
found
variou
infecti
noninfecti
condit
includ
pneumonia
due
legionella
adenoviru
influenza
shortcom
stain
cultur
serolog
detect
mycoplasma
pneumonia
make
pathogen
especi
suitabl
diagnosi
nucleic
acid
test
sever
nucleic
acid
test
pneumonia
current
avail
role
manag
cap
defin
see
chapter
mycoplasma
pneumonia
usual
benign
often
selflimit
infect
excel
prognosi
complet
recoveri
ard
death
report
rare
uniqu
aspect
pneumonia
infect
frequenc
associ
autoimmun
disord
includ
fulmin
autoimmun
hemolyt
anemia
stevensjohnson
syndrom
asept
mening
meningoenceph
pericard
myocard
antimicrobi
therapi
tetracyclin
macrolid
fluoroquinolon
shorten
cours
clinic
symptom
hasten
resolut
radiograph
abnorm
prevent
clinic
relaps
week
minimum
recommend
durat
treatment
respiratori
isol
limit
transmiss
azithromycin
prophylaxi
prevent
infect
close
contact
patient
chlamydophila
pneumonia
epidemiolog
c
pneumonia
formerli
chlamydia
pneumonia
account
case
cap
seroepidemiolog
studi
suggest
c
pneumonia
eventu
caus
infect
gener
popul
primari
infect
c
pneumonia
usual
asymptomat
acut
mild
respiratori
tract
infect
observ
infect
adolesc
young
adult
may
bronchiti
sinus
laryng
tonsil
exacerb
asthma
without
associ
pneumonia
sore
throat
hoars
often
sever
may
preced
pneumonia
week
resolv
pneumonia
onset
result
biphas
ill
erythrocyt
sediment
rate
elev
leukocytosi
elev
pct
may
absent
c
pneumonia
visual
gram
stain
tissu
cultur
requir
grow
pathogen
although
direct
fluoresc
antibodi
detect
c
pneumonia
macrolid
resist
also
compromis
empir
therapi
agent
consequ
seriou
h
influenza
respiratori
tract
infect
treat
secondor
thirdgener
cephalosporin
inhibitor
fluoroquinolon
await
result
suscept
test
epidemiolog
pneumonia
account
cap
person
treat
outpati
pneumonia
requir
hospit
unit
state
estim
case
per
year
per
individu
mycoplasma
infect
seen
throughout
year
outbreak
common
fall
mycoplasma
readili
transmit
person
person
via
aerosol
respiratori
droplet
outbreak
common
famili
close
popul
clinic
pictur
pneumonia
pneumonia
paradigm
atyp
cap
describ
previous
pharyng
cervic
adenopathi
bullou
myring
may
encount
although
latter
common
mycoplasma
pneumonia
pneumococc
pneumoniaot
wide
varieti
exanthem
includ
maculopapular
erupt
urticaria
erythema
multiform
erythema
nodosum
develop
patient
chest
radiograph
usual
show
interstiti
mix
pattern
may
strike
expect
base
chest
physic
find
fig
efig
chest
radiograph
pattern
occasion
encount
well
efig
hemoptysi
rapidli
progress
deterior
septic
shock
leukopenia
rather
leukocytosi
observ
substanti
fraction
case
associ
poor
outcom
radiograph
featur
camrsa
pneumonia
includ
multilobar
opac
andor
cavitari
lesion
efig
case
acquir
hematogen
endocard
endovascular
infect
sign
symptom
relat
underli
endovascular
infect
predomin
pulmonari
infarct
result
septic
embol
pleurit
chest
pain
hemoptysi
often
note
otherwis
respiratori
tract
symptom
mild
absent
chest
radiograph
patient
hematogen
staphylococc
pneumonia
often
reveal
multipl
discret
often
cavitari
shadow
predilect
lower
lobe
fig
purul
sputum
multipl
cluster
larg
gramposit
cocci
particularli
intracellular
strongli
suggest
aureu
pneumonia
fig
organ
easili
recov
sputum
cultur
absenc
mrsa
cultur
even
sever
dose
antibiot
strong
evid
mrsa
caus
pathogen
fewer
pneumonia
due
aspir
associ
posit
blood
cultur
contrast
hematogen
staphylococc
pneumonia
usual
yield
multipl
posit
blood
cultur
camrsa
pleural
effus
often
exud
rather
grossli
purul
still
high
yield
cultur
import
clue
camrsa
presenc
skin
lesion
often
posit
gram
stain
well
avail
nucleic
acid
test
emerg
rapid
sensit
mode
detect
yield
result
time
frame
use
clinic
manag
see
chapter
complet
recoveri
follow
c
pneumonia
infect
rule
fatal
princip
seen
patient
mix
infect
preexist
ill
associ
exacerb
asthma
c
pneumonia
requir
prolong
time
recoveri
twoweek
treatment
macrolid
tetracyclin
doxycyclin
fluoroquinolon
recommend
older
adult
reinfect
often
sever
symptom
aureu
account
less
case
cap
second
third
common
etiolog
patient
cap
requir
icu
admiss
aureu
especi
mrsa
account
nosocomi
pneumonia
nasal
colon
major
sourc
pneumonia
invas
aureu
infect
healthi
adult
carri
organ
transient
anterior
nare
health
care
worker
may
even
higher
carriag
rate
although
organ
easili
transfer
person
person
direct
hand
contact
patient
mrsa
pneumonia
develop
nasal
colon
admiss
indic
case
aureu
hap
due
aureu
transmiss
hospit
communityacquir
strain
mrsa
camrsa
becom
import
cap
pathogen
addit
antibiot
resist
dna
cassett
contain
meca
gene
confer
methicillin
resist
strain
includ
virul
factor
combin
antibiot
resist
multipl
virul
factor
associ
significantli
higher
mortal
typic
hospitalacquir
strain
mrsa
also
caus
cap
usual
patient
risk
factor
hcap
abil
differenti
clinic
hospitaland
communityacquir
case
increasingli
difficult
risk
factor
prior
antibiot
therapi
often
overlap
factor
predispos
patient
acquir
staphylococc
pneumonia
includ
underli
pulmonari
diseas
eg
copd
carcinoma
cystic
fibrosi
chronic
ill
eg
diabet
mellitu
renal
failur
viral
infect
eg
influenza
measl
aureu
includ
camrsa
second
frequenc
pneumonia
caus
postinfluenza
bacteri
pneumonia
postinfluenza
cap
due
camrsa
associ
high
frequenc
complic
mortal
pneumonia
due
hematogen
spread
aureu
uniqu
type
pneumonia
usual
consequ
intraven
drug
use
septic
embol
endocard
infect
vascular
site
camrsa
pneumonia
seen
young
patient
without
underli
ill
clinic
present
sever
case
includ
high
fever
hypotens
treatment
pneumonia
bind
inactiv
pulmonari
surfact
term
gramneg
bacillari
pneumonia
refer
infect
caus
member
two
group
enterobacteriacea
pseudomonadacea
aerob
gramneg
bacilli
infect
caus
haemophilu
legionella
anaerob
usual
exclud
categor
epidemiolog
common
caus
hap
gramneg
bacilli
may
caus
cap
cap
due
gramneg
bacilli
often
sever
frequent
requir
icu
care
patient
icu
especi
undergo
mechan
ventil
highest
risk
develop
gramneg
bacillari
pneumonia
enterobacteriacea
normal
colon
digest
tract
pneumonia
usual
result
aspir
oropharyng
flora
although
uncommon
healthi
nonhospit
individu
oropharyng
colon
gramneg
bacilli
greatli
increas
hospit
antimicrobi
use
risk
aspir
increas
comorbid
cerebrovascular
accid
seizur
anesthesia
occasion
contamin
home
respiratori
therapi
equip
directli
introduc
gramneg
rod
respiratori
tract
final
enterobacteriacea
pneumonia
may
result
hematogen
seed
infect
anatom
site
among
enterobacteriacea
escherichia
coli
singl
frequent
caus
cap
classic
caus
communityacquir
gramneg
bacillari
pneumonia
k
pneumonia
friedland
pneumonia
caus
fewer
cap
nosocomi
pneumonia
alcohol
abus
common
underli
condit
communityacquir
k
pneumonia
pneumonia
underli
condit
predispos
klebsiella
infect
diabet
mellitu
copd
clinic
manifest
klebsiella
cap
syndrom
pleurit
chest
pain
hemoptysi
bloodi
sputum
occasion
currant
jelli
appear
classic
rare
seen
clinic
manifest
enterobacteriacea
pneumonia
suffici
uniqu
distinguish
infect
pneumonia
due
caus
laboratori
abnorm
nonspecif
neutropenia
associ
poor
prognosi
chest
radiograph
often
demonstr
lower
lobe
bronchopneumonia
efig
often
bilater
classic
radiograph
appear
klebsiella
pneumonia
upper
lobe
consolid
especi
right
fig
bulg
bow
fissur
manifest
uncommon
klebsiella
also
caus
lung
abscess
efig
patient
hcap
microbiolog
diagnosi
enterobacteriacea
pneumonia
suspect
sputum
gram
stain
reveal
larg
number
uniformappear
gramneg
rod
even
appropri
antibiot
durat
fever
need
icu
care
often
prolong
aureu
pneumonia
particularli
camrsa
local
complic
staphylococc
pneumonia
includ
empyema
abscess
format
infect
spread
hematogen
central
nervou
system
bone
joint
skin
kidney
caviti
necrot
tissu
may
prevent
adequ
local
antibiot
penetr
wherea
unrecogn
incomplet
drain
empyema
may
prolong
fever
manifest
due
strain
secret
pantonvalentin
leukocidin
one
exotoxin
produc
aureu
pleuroscopi
decort
requir
larg
percentag
case
empyema
mortal
aureu
cap
gener
higher
etiolog
mortal
methicillinsensit
strain
aureu
cap
follow
influenza
report
mortal
greater
even
methicillinresist
treatment
choic
methicillinsuscept
aureu
pneumonia
penicillinaseresist
penicillin
eg
oxacillin
gday
firstgener
cephalosporin
therapi
day
adequ
uncompl
case
week
treatment
recommend
patient
bacteremia
cavit
penicillinallerg
patient
clindamycin
linezolid
use
treatment
mrsa
pneumonia
challeng
incid
cap
caus
health
careassoci
mrsa
camrsa
strain
increas
although
resist
vancomycin
still
rare
mic
shift
upward
mic
greater
associ
clinic
failur
higherrisk
patient
vap
underli
renal
insuffici
linezolid
found
better
clinic
respons
rate
vancomycin
although
differ
patient
surviv
variabl
camrsa
vancomycin
therapi
alon
associ
signific
failur
rate
addit
clindamycin
use
linezolid
associ
improv
outcom
small
case
seri
unlik
mrsa
skin
infect
clindamycin
fluoroquinolon
tmpsmx
unreli
sever
camrsa
case
daptomycin
ineffect
drug
initi
therapi
possibl
enterobacteriacea
pneumonia
must
select
use
knowledg
local
antibiot
resist
pattern
patient
seriou
infect
twodrug
regimen
aminoglycosid
broadspectrum
carbapenem
recommend
treatment
suscept
result
known
monotherapi
may
reason
immunocompet
patient
mild
moder
diseas
infect
suscept
strain
proteu
morganella
k
pneumonia
e
coli
recommend
empir
therapi
hap
list
tabl
although
local
resist
pattern
must
taken
account
epidemiolog
p
aeruginosa
uncommon
caus
cap
except
specif
risk
group
although
one
larg
studi
spain
found
cap
due
p
aeruginosa
studi
found
substanti
lower
rate
one
major
risk
factor
pseudomona
cap
structur
lung
diseas
cystic
fibrosi
bronchiectasi
sever
copd
forc
expiratori
volum
second
anoth
risk
factor
hiv
infect
especi
mark
defici
cell
pseudomona
pneumonia
aid
patient
sever
mortal
rate
high
associ
cavit
even
patient
profound
tcell
defici
incid
pseudomona
pneumonia
decreas
widespread
avail
combin
antiretrovir
therapi
pseudomona
pneumonia
rare
normal
host
develop
exposur
aerosol
contamin
water
hot
tub
p
aeruginosa
lead
caus
nosocomi
pneumonia
particularli
frequent
caus
vap
prolong
endotrach
intub
prior
antibiot
therapi
especi
broadspectrum
antibiot
major
risk
factor
pseudomona
vap
nonferment
maltophilia
b
cepacia
caus
pneumonia
patient
prolong
broadspectrum
antibiot
therapi
associ
high
mortal
rate
b
cepacia
also
found
outpati
cystic
fibrosi
clinic
manifest
clinic
pictur
pneumonia
due
p
aeruginosa
efig
indistinguish
enterobacteriacea
bacteremia
slightli
common
gramneg
pathogen
physic
examin
may
reveal
ecthyma
gangrenosum
leukopenia
common
propens
invad
vascular
tissu
make
pseudomona
common
caus
cavitari
pneumonia
efig
hospit
immunocompromis
patient
empyema
develop
microbiolog
diagnosi
gramstain
sputum
patient
pseudomona
pneumonia
typic
show
mani
slender
gramneg
bacilli
fig
neutrophil
commonli
abund
sputum
except
neutropen
patient
sinc
pseudomona
gramneg
bacilli
colon
oropharynx
hospit
debilit
patient
gram
stain
result
patient
mislead
endotrach
intub
patient
absenc
pseudomona
cultur
strong
evid
pseudomona
caus
patient
pneumonia
organ
typic
easi
recov
fig
sputum
cultur
alon
nonspecif
enterobacteriacea
either
nonintub
intub
patient
oropharyng
colon
one
major
reason
interest
quantit
cultur
approach
distinguish
colon
infect
clinic
cours
enterobacteriacea
pneumonia
fatal
rate
bacteremia
neutropenia
advanc
age
contribut
poor
prognosi
destruct
pulmonari
alveolar
septa
may
lead
cavit
treatment
treatment
seriou
infect
due
enterobacteriacea
complic
widespread
antimicrobi
resist
extendedspectrum
carbapenemas
fluoroquinolon
aminoglycosid
resist
common
patient
infect
enterobacteracea
due
region
institut
variat
frequenc
resist
specif
drug
class
effus
empyema
nosocomi
acinetobact
pneumonia
less
dramat
present
similar
hospitalacquir
gramneg
pneumonia
microbiolog
diagnosi
examin
expector
sputum
usual
purul
may
reveal
predomin
pair
gramneg
coccobacilli
resembl
neisseria
haemophilu
moraxella
speci
bacteremia
complic
communityacquir
often
nosocomi
acinetobact
pneumonia
clinic
cours
mortal
rate
communityacquir
acinetobact
pneumonia
approach
patient
greatest
risk
death
leukopenia
empyema
fatal
rate
nosocomi
acinetobact
pneumonia
determin
sever
underli
diseas
treatment
commun
isol
baumannii
suscept
amikacin
tobramycin
ceftazidim
carbapenem
doxycyclin
nosocomi
acinetobact
speci
resist
aminoglycosid
therefor
reliabl
treat
carbapenem
poor
outcom
common
investig
report
success
treatment
highli
resist
isol
ampicillinsulbactam
colistin
resist
antimicrobi
carbapenem
aminoglycosid
fluoroquinolon
even
polymyxin
b
colistin
increasingli
common
among
nosocomi
isol
l
pneumophila
caus
epidem
sporad
infect
pattern
may
seen
either
commun
hospit
outbreak
link
contamin
potabl
water
system
ultrason
mist
devic
whirlpool
bath
aircondit
condens
waterevapor
system
legionella
acquir
inhal
contamin
aerosol
aspir
sporad
case
l
pneumophila
pneumonia
due
serogroup
account
cap
immunocompet
host
l
pneumophila
one
common
caus
sever
cap
certain
commun
risk
factor
includ
exposur
contamin
water
immunosuppress
cigarett
use
diabet
cancer
endstag
renal
diseas
alcohol
use
infect
l
pneumophila
common
specif
geograph
region
mediterranean
northeastern
unit
state
addit
l
pneumophila
legionella
speci
identifi
mani
legionella
micdadei
legionella
longbeacha
produc
pneumon
ill
indistinguish
l
pneumophila
much
less
known
epidemiolog
nonpneumophila
legionella
infect
also
appear
water
soilrel
sourc
immunosuppress
appear
major
host
risk
speci
incub
period
legionella
pneumonia
day
lethargi
headach
fever
recur
rigor
anorexia
clinic
cours
mortal
communityacquir
p
aeruginosa
pneumonia
exceed
person
vap
due
p
aeruginosa
mortal
rate
prognosi
neutropen
patient
p
aeruginosa
pneumonia
particularli
poor
p
aeruginosa
vap
recur
case
approxim
half
due
new
strain
treatment
p
aeruginosa
pneumonia
initi
treat
two
antimicrobi
agent
expect
activ
isol
region
aminoglycosid
antipseudomon
antibiot
especi
true
bacterem
neutropen
patient
amikacin
reliabl
activ
aminoglycosid
region
antibiot
descend
order
probabl
activ
p
aeruginosa
carbapenem
imipenem
meropenem
acylureidopenicillin
eg
piperacillin
cefepim
ceftazidim
although
fluoroquinolon
particularli
ciprofloxacin
initi
possess
good
intrins
activ
p
aeruginosa
resist
common
make
empir
fluoroquinolon
monotherapi
hazard
resist
emerg
pseudomona
cours
fluoroquinolon
monotherapi
maltophilia
inher
resist
standard
antibiot
tmpsmx
reliabl
agent
fluoroquinolon
ticarcillinclavulan
activ
strain
isol
maltophilia
may
becom
resist
face
seemingli
effect
therapi
b
cepacia
may
suscept
acylureidopenicillin
ceftazidim
tmpsmx
fluoroquinolon
minocyclin
chloramphenicol
resist
rate
higher
isol
patient
cystic
fibrosi
epidemiolog
baumannii
may
caus
either
cap
hapvap
acinetobact
caus
cap
hot
climat
dri
humid
becom
one
common
caus
cap
southeast
asia
unit
state
acinetobact
cap
commonli
seen
male
alcohol
risk
acinetobact
vap
vari
wide
region
health
care
facil
nosocomi
infect
caus
acinetobact
show
season
variat
peak
late
summer
similar
pattern
cap
patient
acinetobact
cap
often
present
acut
ill
may
leukopenia
pleural
micdadei
legionella
speci
may
stain
weakli
acidfast
earli
infect
sputum
gram
stain
patient
legionella
pneumonia
contain
polymorphonuclear
leukocyt
sensit
cultur
respiratori
specimen
low
despit
use
appropri
media
cultur
diagnosi
l
pneumophila
infect
often
requir
invas
procedur
least
patient
legionella
infect
produc
sputum
rare
legionella
recov
blood
pleural
fluid
extrapulmonari
site
legionella
urinari
antigen
test
current
commonli
use
method
diagnosi
sensit
specif
greater
l
pneumophila
serogroup
test
limit
singl
speci
serogroup
sensit
direct
fluoresc
antibodi
assay
sputum
rang
specif
greater
use
hinder
difficulti
obtain
sputum
patient
expertis
requir
interpret
requir
specif
antibodi
multipl
legionella
speci
serogroup
polymeras
chain
reactionbas
assay
sputum
greater
sensit
greater
specif
avail
like
becom
widespread
clinic
respons
appropri
antibiot
therapi
usual
observ
within
first
hour
contrast
radiograph
find
may
temporarili
continu
progress
despit
observ
clinic
improv
ultim
take
month
resolv
acut
renal
failur
oliguria
often
independ
shock
myoglobinuria
may
develop
myalgia
frequent
earli
symptom
sever
day
cough
becom
pronounc
occasion
wateri
purul
sputum
develop
dyspnea
promin
half
case
one
third
patient
complain
pleurit
chest
pain
extrapulmonari
manifest
may
overshadow
respiratori
complaint
gastrointestin
wateri
diarrhea
nausea
vomit
abdomin
pain
neurolog
symptom
sign
headach
confus
obtund
seizur
hallucin
particularli
noteworthi
patient
may
appear
acut
ill
temperatur
reach
c
one
third
patient
typic
sustain
may
accompani
rel
bradycardia
physic
find
usual
limit
chest
includ
pleural
friction
rub
gener
abdomin
tender
hepatomegali
splenomegali
cutan
rash
nuchal
rigid
focal
neurolog
deficit
describ
hyponatremia
hypophosphatemia
present
half
sever
case
mild
elev
serum
creatinin
creatin
phosphokinas
liver
enzym
also
common
hematuria
proteinuria
occasion
frank
rhabdomyolysi
may
leukopenia
thrombocytopenia
especi
sever
ill
patient
cold
agglutinin
may
present
infect
due
pneumonia
chest
radiograph
find
typic
lag
behind
earli
clinic
ill
fig
small
pleural
effus
develop
may
preced
parenchym
process
multilobar
opac
commonli
seen
efig
particularli
chest
ct
frank
cavit
rare
seen
legionella
obligatori
aerob
fastidi
gramneg
bacilli
stain
poorli
gram
stain
see
chapter
imag
may
demonstr
dens
segment
opacif
multipl
small
lucent
area
lung
necrosi
cm
diamet
usual
without
airfluid
level
efig
absenc
appropri
treatment
lesion
may
evolv
primari
lung
abscess
efig
empyema
patient
commonli
present
fatigu
lowgrad
fever
weight
loss
product
cough
sever
week
episod
loss
conscious
approxim
half
describ
putrid
sputum
may
hemoptysi
patient
appear
chronic
ill
toxic
temperatur
c
patient
singl
lung
abscess
greater
cm
diamet
detect
depend
lung
segment
radiographi
fig
abscess
may
multilocular
occasion
multipl
abscess
locat
differ
lung
segment
approxim
patient
dialysi
may
requir
mani
patient
note
linger
fatigu
weak
month
follow
legionella
pneumonia
mortal
communityacquir
legionella
pneumonia
approxim
poor
clinic
outcom
associ
immunodefici
comorbid
delay
initi
appropri
therapi
need
ventilatori
support
dialysi
azithromycin
fluoroquinolon
superior
erythromycin
clarithromycin
treatment
legionella
infect
although
never
use
alon
addit
rifampin
advis
patient
sever
ill
immunocompromis
antibiot
continu
day
immunocompet
patient
decreas
rate
relaps
mix
aerob
anaerob
infect
usual
complic
macroaspir
oropharyng
content
rare
caus
includ
ruptur
esophagu
extens
intraabdomin
abscess
underli
pulmonari
condit
malign
pulmonari
infarct
present
patient
anaerob
lung
infect
although
acut
complic
macroaspir
larg
due
chemic
injuri
pneumon
mendelson
syndrom
andor
infect
pathogen
aerob
oral
flora
mani
episod
later
result
emerg
mix
aerob
anaerob
pneumonia
anaerob
infect
present
four
differ
syndrom
chemic
pneumon
aspir
pneumonia
anaerob
pleuropneumonia
primari
anaerob
empyema
chemic
pneumon
preced
anaerob
pneumonia
character
acut
onset
hypoxemia
fever
cough
often
dri
dyspnea
pleurit
pain
foul
sputum
hemoptysi
characterist
anaerob
lung
abscess
absent
stage
risk
infect
depend
natur
inoculum
mani
case
aspir
pneumon
inflammatori
alon
infecti
imag
may
demonstr
bronchopneumon
opac
usual
lobar
consolid
aspirationpron
segment
lung
eg
posterior
segment
right
upper
lobe
superior
segment
right
lower
lobe
see
efig
ard
common
complic
aspir
low
ph
gastric
fluid
aspir
pneumonia
indistinguish
either
cap
hap
efig
except
seen
patient
risk
factor
macroaspir
rapid
develop
pulmonari
opac
short
period
time
may
suggest
diagnosi
aspir
pneumonia
fig
efig
high
concentr
amylas
pepsinogen
bal
fluid
suggest
entiti
local
opac
depend
lung
segment
less
discrimin
valu
anaerob
pleuropneumonia
character
necrosi
suppur
lung
parenchyma
earli
cours
uncompl
aspir
pneumonia
gener
respond
promptli
appropri
antibiot
fever
resolv
within
day
chest
radiograph
normal
within
week
fever
resolv
slowli
anaerob
pleuropulmonari
infect
closur
abscess
caviti
see
efig
resorpt
empyema
collect
may
requir
month
fatal
rate
low
adequ
treat
patient
except
necrot
pneumonia
mortal
approach
chronic
lung
abscess
complic
brain
abscess
metastat
abscess
secondari
amyloidosi
lifethreaten
hemoptysi
bronchopleur
fistula
empyema
necessitan
ruptur
chest
wall
complic
current
rare
emerg
resist
mandat
penicillin
g
ampicillin
longer
drug
choic
treatment
patient
seriou
anaerob
pleuropulmonari
infect
resist
among
bacteroid
speci
also
among
prevotella
f
nucleatum
strain
empir
treatment
seriou
anaerob
pleuropulmonari
infect
requir
use
inhibitor
eg
ampicillinsulbactam
ticarcillinclavulan
piperacillintazobactam
clindamycin
frequent
simultan
presenc
aerob
metronidazol
monotherapi
adequ
suspect
anaerob
pneumonia
occasion
pulmonari
isol
resist
one
agent
exampl
eikenella
corroden
resist
clindamycin
carbapenem
monotherapi
also
effect
gener
provid
unnecessarili
broad
coverag
ten
day
total
treatment
usual
adequ
uncompl
pneumon
necrot
pneumonia
abscess
empyema
requir
prolong
parenter
therapi
achiev
clinic
improv
extend
cours
oral
therapi
often
requir
sever
month
may
requir
cure
drainag
empyema
fluid
requir
surgic
resect
anaerob
lung
abscess
almost
never
indic
bronchoscopi
use
exclud
underli
malign
patient
without
risk
factor
ie
edentul
patient
two
differ
clinic
pattern
treatment
failur
pneumonia
describ
progress
pneumonia
clinic
deterior
includ
respiratori
failur
septic
shock
nonrespond
pneumonia
clinic
improv
achiev
fever
clinic
symptom
persist
treat
outpati
inpati
evalu
respons
undertaken
hour
antibiot
treatment
repres
median
time
requir
achiev
clinic
improv
addit
clinic
evalu
reduct
procalcitonin
pct
level
day
treatment
correl
clinic
respons
level
certain
biomark
mainli
pct
primari
anaerob
empyema
usual
due
milleriintermediu
see
efig
rather
anaerob
howev
anaerob
still
play
signific
role
case
pleural
manifest
may
domin
less
evid
pneumonia
anaerob
empyema
also
seen
absenc
parenchym
lung
infect
empyema
develop
associ
esophag
ruptur
subphren
intraabdomin
abscess
inform
pleural
empyema
chapter
gram
stain
sputum
examin
bronchoscop
obtain
specimen
patient
anaerob
pneumonia
reveal
numer
polymorphonuclear
leukocyt
abund
intracellular
extracellular
bacteria
typic
mixtur
gram
stain
reaction
morpholog
seen
includ
palestain
gramneg
rod
taper
end
suggest
fusobacterium
nucleatum
small
palestain
gramneg
coccobacilli
chain
tini
gramposit
cocci
endogen
flora
upper
respiratori
tract
predominantli
consist
anaerob
bacteria
cultur
expector
sputum
appropri
diagnosi
anaerob
infect
care
techniqu
recoveri
averag
bacteri
isol
anaerob
possibl
case
mix
aerobicanaerob
pneumonia
empyema
common
anaerob
pleuropulmonari
infect
includ
f
nucleatum
prevotella
porphyromona
peptostreptococcu
microaerophil
streptococcu
major
aerob
facult
organ
recov
conjunct
anaerob
streptococcu
speci
although
aureu
variou
enter
gramneg
bacilli
pseudomona
may
also
isol
signific
often
question
molecular
techniqu
often
identifi
anaerob
cultur
neg
case
varieti
pathogen
less
common
caus
pneumonia
agent
may
suspect
presenc
uniqu
risk
factor
present
may
diagnos
result
cultur
varieti
speci
within
two
genera
actinomycetacea
famili
actinomyc
propionibacterium
normal
harmless
commens
oropharynx
caus
subacut
chronic
pulmonari
infect
virtual
indistinguish
pulmonari
actinomycosi
follow
aspir
oropharyng
materi
periodont
dental
diseas
increas
risk
cervicofaci
invas
pneumonia
patient
year
old
men
outnumb
women
ratio
patient
actinomycosi
appear
chronic
ill
toxic
constitut
symptom
includ
fatigu
weight
loss
lowgrad
fever
may
present
week
month
diagnosi
often
mimic
present
chronic
fungal
infect
tuberculosi
malign
fever
may
absent
patient
gradual
develop
product
cough
pleurit
chest
pain
hemoptysi
putrid
sputum
unusu
cervicofaci
involv
rare
observ
patient
thorac
involv
imag
find
classic
actinomycosi
direct
extens
caviti
mass
interlobar
fissur
commonli
chang
confin
singl
lobe
one
small
cavitari
lesion
efig
advanc
case
find
may
distinct
penetr
chest
wall
andor
destruct
adjac
bone
tissu
efig
member
actinomyc
propionibacterium
genera
gramposit
diphtheroid
filament
branch
bacilli
strain
grow
best
anaerob
condit
although
also
grow
aerob
patient
cutan
chest
wall
sinu
best
mean
establish
diagnosi
actinomycosi
detect
sulfur
granul
crush
stain
form
characterist
pattern
gramposit
branch
filament
efig
organ
usual
recov
cultur
materi
provid
anaerob
condit
maintain
specimen
diagnosi
actinomycot
parenchym
lesion
difficult
sulfur
granul
rare
present
sputum
recoveri
organ
sputum
cultur
unreli
organ
may
colon
without
invad
mucos
surfac
definit
diagnosi
depend
demonstr
characterist
histopatholog
cultur
steril
bodi
fluid
tissu
biopsi
organ
commonli
identifi
includ
haemophilu
actinobacillu
actinomycetemcomitan
prevotella
addit
actinomyc
propionibacterium
complic
pulmonari
actinomycosi
relat
abil
invad
across
anatom
barrier
pleural
empyema
cutan
thorac
sinus
mediastin
pericard
vertebr
osteomyel
infrequ
metastat
infect
includ
brain
skin
bone
commonli
seen
pulmonari
actinomycosi
variant
eg
cervicofaci
diseas
still
unusu
adequ
therapi
death
actinomycosi
rare
prolong
antibiot
treatment
key
cure
actinomycosi
actinomyc
univers
suscept
penicillin
g
given
intraven
dose
million
unit
daili
week
follow
least
month
oral
penicillin
v
ampicillin
multipl
drug
also
success
use
prolong
therapi
essenti
polymicrobi
infect
presenc
organ
may
requir
modif
therapi
anaerob
present
treatment
choic
describ
anaerob
pneumonia
recommend
occas
clindamycin
fail
concomit
infect
h
actinomycetemcomitan
rare
surgic
resect
requir
cure
exposur
bird
classic
risk
factor
psittacosi
multipl
speci
harbor
organ
case
acquir
canari
parakeet
cockatiel
parrot
pigeon
although
infect
bird
typic
ill
asymptomat
fecal
carriag
c
psittaci
detect
blood
tissu
feather
fece
infect
bird
human
acquisit
typic
via
inhal
contamin
bird
excreta
although
approxim
case
report
owner
infect
pet
bird
may
sporad
case
occasion
outbreak
without
histori
known
bird
exposur
histori
exposur
like
sever
diseas
symptom
psittacosi
may
develop
abruptli
high
fever
chill
may
evolv
slowli
headach
arthralgia
pain
myalgia
especi
head
neck
promin
featur
sever
cough
develop
may
either
dri
hack
product
mucoid
sputum
chest
pain
dyspnea
present
extens
pulmonari
involv
temperatur
c
c
frequent
accompani
rel
bradycardia
splenomegali
occasion
pale
macular
rash
horder
spot
seen
hematolog
blood
chemistri
find
nonspecif
except
occasion
find
consist
granulomat
hepat
c
psittaci
oblig
intracellular
parasit
stain
gram
method
seen
larg
intracytoplasm
inclus
infect
cell
stain
giemsa
stain
cultiv
organ
requir
tissu
cultur
pose
threat
laboratori
personnel
perform
special
facil
nucleic
acid
test
offer
rapid
altern
method
diagnosi
higher
sensit
cultur
absenc
avail
nucleic
acid
test
diagnosi
psittacosi
made
demonstr
fourfold
rise
complementfix
antibodi
pair
acut
convalesc
serum
singl
titer
greater
consid
presumpt
evid
infect
patient
compat
ill
antibodi
crossreact
c
burnetii
brucella
treatment
doxycyclin
recommend
clinic
respons
may
slow
risk
relaps
therapi
given
minimum
week
fever
resolv
chloramphenicol
erythromycin
azithromycin
moxifloxacin
also
vitro
activ
clinic
experi
use
drug
treat
c
psittaci
limit
casefat
rate
antimicrobi
therapi
unusu
complic
includ
respiratori
failur
enceph
hepat
dissemin
intravascular
coagul
renal
failur
endocard
worldwid
q
fever
particular
problem
farm
commun
europ
north
america
australia
c
burnetii
asymptomat
infect
wide
varieti
domest
wild
anim
well
tick
transmiss
human
primarili
via
exposur
urin
fece
placenta
unpasteur
milk
infect
anim
cow
sheep
goat
common
outbreak
happen
tanneri
dairi
woolrend
plant
among
laboratori
personnel
household
member
expos
infect
cat
dog
parturit
follow
incub
period
week
atyp
pneumonia
syndrom
develop
infect
person
high
temperatur
c
rel
bradycardia
conjunct
hepatosplenomegali
chest
crackl
may
detect
rash
typic
absent
c
burnetii
small
oblig
intracellular
bacterium
cultur
standard
media
visual
gram
stain
high
infect
organ
cultur
attempt
experienc
personnel
biosafeti
laboratori
present
diagnosi
usual
reli
fourfold
rise
antibodi
titer
acut
convalesc
serum
sampl
nucleic
acid
test
like
provid
rapid
diagnosi
would
use
guid
treatment
decis
although
patient
may
acut
ill
present
diseas
rare
fatal
gener
run
cours
week
patient
particularli
older
adult
prolong
ill
concern
aspect
q
fever
potenti
chronic
vascular
complic
includ
endocard
vascular
graft
infect
infect
aortic
aneurysm
acut
q
fever
pneumonia
pregnanc
often
associ
fetal
loss
tetracyclin
especi
doxycyclin
firstlin
therapi
q
fever
quinolon
excel
vitro
activ
may
advantag
treatment
meningoenceph
nocardia
asteroid
etiolog
agent
pulmonari
dissemin
case
nocardiosi
although
sever
speci
eg
nocardia
brasiliensi
also
associ
human
infect
organ
widespread
natur
primarili
soil
respiratori
tract
skin
gastrointestin
tract
portal
infect
dysfunct
cellmedi
immun
much
lesser
extent
immunoglobulin
defect
predispos
infect
thu
infect
rate
increas
patient
lymphoma
leukemia
cush
diseas
aid
receiv
immunosuppress
medic
recent
case
report
lung
heart
stemcel
transplant
recipi
person
pulmonari
alveolar
proteinosi
also
increas
risk
nonetheless
approxim
half
patient
nocardiosi
develop
known
underli
medic
disord
although
nocardiosi
actinomycosi
clinic
similar
infect
lower
respiratori
tract
nocardiosi
distinguish
less
procliv
sinu
tract
format
greater
tendenc
hematogen
dissemin
healthi
impair
host
dissemin
may
involv
almost
everi
organ
system
central
nervou
system
skin
common
mani
patient
pulmonari
nocardiosi
lowgrad
fever
fatigu
weight
loss
product
cough
pleurit
chest
pain
week
seek
medic
attent
howev
immunosuppress
patient
present
acut
fulmin
pneumonia
physic
examin
nonspecif
unless
site
dissemin
obviou
neurolog
sign
mass
lesion
may
present
cutan
dissemin
appear
multipl
subcutan
abscess
without
sinu
tract
imag
commonli
demonstr
local
bronchopneumonia
lobar
consolid
efig
may
also
solitari
multipl
efig
miliari
nodul
abscess
efig
pleural
effus
develop
one
third
case
nocardia
speci
gramposit
bacilli
appear
bead
branch
filament
unlik
anaerob
actinomycetacea
nocardia
requir
aerob
growth
condit
usual
weakli
acidfast
stain
modifi
ziehlneelsen
method
efig
nocardia
cultiv
convent
blood
agar
sabouraud
medium
growth
may
appar
day
although
occasion
colon
upper
respiratori
tract
recoveri
nocardia
cultur
sputum
invas
obtain
materi
highli
suggest
diagnosi
mortal
approach
central
nervou
system
lesion
less
pulmonari
diseas
vitro
synergi
tmpsmx
becom
standard
treatment
case
sulfa
allergi
resist
organ
minocyclin
amikacin
cefotaxim
imipenem
linezolid
may
use
choic
alway
guid
result
suscept
test
prolong
therapi
need
prevent
relaps
adequ
drainag
excis
abscess
empyema
crucial
adjunct
antimicrobi
therapi
endem
area
southeast
asia
northern
australia
melioidosi
may
common
caus
sever
cap
b
pseudomallei
found
soil
veget
water
throughout
tropic
region
latitud
degre
n
degre
acquisit
organ
cutan
inocul
inhal
patient
regular
contact
water
soil
risk
factor
diseas
includ
diabet
alcohol
renal
diseas
typhoon
episod
heavi
rain
may
increas
risk
acut
fulmin
pneumonia
case
happen
raini
season
melioidosi
produc
either
acut
fulmin
pneumonia
indol
cavitari
diseas
clinic
manifest
acut
melioidosi
includ
high
fever
prostrat
dyspnea
pleurit
chest
pain
purul
sputum
hemoptysi
concomit
bacteremia
common
chest
radiograph
typic
show
diffus
miliari
nodul
may
expand
cavit
subacut
chronic
b
pseudomallei
pneumonia
milder
often
manifest
period
latenc
patient
may
entir
asymptomat
ie
abnorm
radiograph
present
ill
clinic
radiograph
indistinguish
tuberculosi
b
pseudomallei
aerob
gramneg
bacillu
grow
readili
routin
cultur
media
despit
improv
recognit
treatment
melioidosi
still
associ
high
morbid
mortal
b
pseudomallei
sensit
usual
cap
antibiot
usual
suscept
carbapenem
ceftazidim
tmpsmx
optim
treatment
dissemin
lifethreaten
melioidosi
requir
initi
intens
therapi
carbapenem
ceftazidim
follow
month
tmpsmx
rhodococcu
equi
may
caus
lung
abscess
pneumonia
case
seen
set
impair
cellmedi
immun
eg
high
dose
corticosteroid
hiv
infect
solid
organ
transplant
person
histori
anim
exposur
ill
develop
subacut
mimick
mycobacteri
fungal
infect
chest
radiograph
often
show
upper
lobe
nodul
gradual
cavit
organ
intracellular
gramposit
bacillu
may
stain
weakli
acidfast
much
smaller
mycobacteria
effect
regimen
appear
prolong
cours
vancomycin
erythromycin
addit
rifampin
may
use
see
chapter
although
b
anthraci
detect
mani
agricultur
region
anthrax
rare
infect
develop
world
spore
transmiss
agent
infect
resid
soil
water
veget
primarili
infect
larg
herbivor
anim
eg
cow
sheep
hors
human
infect
spore
via
contact
contamin
anim
anim
product
eg
anim
hide
wool
b
anthraci
proven
agent
bioterror
manifest
anthrax
cutan
gastrointestin
inhal
woolsort
diseas
inhal
anthrax
sever
diseas
result
germin
b
anthraci
spore
lung
drain
lymph
node
follow
growth
veget
form
bacteria
product
edema
toxin
lethal
toxin
clinic
ill
begin
insidi
fever
malais
nonproduct
cough
precordi
pain
stage
follow
rapid
pulmonari
deterior
dyspnea
stridor
chest
pain
tachypnea
cyanosi
nausea
vomit
drench
night
sweat
diffus
edema
neck
anterior
chest
may
evid
due
action
edema
toxin
mening
common
complic
radiograph
lung
parenchyma
initi
clear
widen
mediastinum
bilater
pleural
effus
clue
inhal
anthrax
mediastin
widen
seen
inhal
anthrax
case
although
chest
ct
scan
may
requir
defin
characterist
later
find
includ
vascular
engorg
lung
parenchym
opac
b
anthraci
larg
facult
gramposit
rod
form
spore
organ
grow
readili
routin
cultur
media
rapidli
recov
cultur
blood
sputum
pleural
fluid
advanc
diseas
organ
may
demonstr
gram
stain
peripher
blood
b
anthraci
detect
nasal
swab
person
expos
anthrax
spore
predict
valu
test
diagnos
clinic
diseas
illdefin
treatment
recommend
inhal
anthrax
may
affect
resist
potenti
need
treat
mass
casualti
current
recommend
inhal
anthrax
call
initi
treatment
ciprofloxacin
plu
one
two
addit
antibiot
vitro
activ
clindamycin
vancomycin
imipenem
meropenem
chloramphenicol
penicillin
ampicillin
rifampin
clarithromycin
isol
suscept
therapi
chang
fluoroquinolon
highdos
penicillin
g
doxycyclin
intraven
therapi
may
convert
oral
therapi
patient
condit
stabil
sinc
pulmonari
system
anthrax
associ
high
mortal
rate
therapi
fdaapprov
human
monoclon
antibodi
raxibacumab
anthrax
lethal
toxin
recommend
adjunct
antimicrobi
therapi
treatment
day
recommend
elimin
spore
could
sourc
relaps
although
report
mortal
rate
high
patient
inhal
anthrax
surviv
anthrax
attack
unit
state
see
chapter
although
f
tularensi
recov
numer
insect
speci
wild
domest
mammal
throughout
temper
zone
northern
hemispher
fewer
case
tularemia
per
year
report
unit
state
human
acquir
infect
follow
direct
contact
tissu
infect
anim
skin
eat
infect
anim
bite
infect
tick
deerfli
inhal
contamin
aerosol
person
engag
landscap
agricultur
activ
gener
aerosol
endem
area
particular
risk
develop
pneumon
tularaemia
effici
aerosol
transmiss
f
tularensi
regard
potenti
agent
bioterror
pneumonia
develop
inhal
contamin
aerosol
complic
bacteremia
clinic
manifest
typic
begin
abruptli
fever
chill
malais
headach
shortli
thereaft
dyspnea
cough
chest
pain
may
develop
chest
radiograph
usual
normal
onset
day
follow
aerosol
exposur
ultim
show
diffus
bronchopneumonia
often
hilar
adenopathi
pleural
effus
common
may
seen
without
parenchym
involv
f
tularensi
fastidi
pleomorph
gramneg
bacillu
rare
visual
gram
stain
sputum
requir
special
enrich
media
optim
recoveri
cultur
hazard
natur
organ
cultur
best
undertaken
refer
laboratori
organ
also
rapidli
identifi
tissu
secret
exud
use
immunohistochem
techniqu
retrospect
diagnosi
accomplish
demonstr
fourfold
rise
agglutin
titer
singl
titer
greater
compat
either
past
current
infect
mortal
high
pneumon
tularemia
suspect
treat
appropri
although
gentamicin
use
success
streptomycin
remain
prefer
therapi
ciprofloxacin
accept
altern
agent
doxycyclin
chloramphenicol
associ
higher
relaps
rate
requir
longer
durat
therapi
ceftriaxon
unsatisfactori
despit
vitro
activ
known
aerosol
exposur
f
tularensi
prophylaxi
doxycyclin
ciprofloxacin
day
recommend
plagu
yersinia
pesti
see
chapter
plagu
typic
associ
ground
squirrel
rabbit
prairi
dog
rat
small
ground
anim
rodent
flea
respons
transmiss
organ
anim
host
human
becom
infect
bitten
infect
rodent
flea
handl
infect
anim
carcass
inhal
aerosol
human
anim
pulmonari
involv
unit
state
case
plagu
rural
new
mexico
arizona
california
diseas
sever
potenti
aerosol
transmiss
pesti
also
regard
potenti
bioterror
weapon
three
clinic
form
infect
exist
pneumon
bubon
septicem
although
pneumon
form
present
primari
pneumonia
lung
may
also
involv
bubon
septicem
infect
plagu
pneumonia
may
develop
day
initi
exposur
earli
cours
ill
patient
experi
fever
toxic
follow
chest
pain
product
cough
dyspnea
hemoptysi
presenc
hemoptysi
caus
confus
hantaviru
pulmonari
syndrom
whose
geograph
distribut
overlap
plagu
unit
state
pulmonari
diseas
complic
bubon
plagu
pain
adenopathi
also
note
septicem
form
patient
may
show
sign
septic
shock
chest
radiograph
case
pneumon
plagu
commonli
reveal
bilater
lower
lobe
alveolar
opac
may
also
nodul
adenopathi
pleural
effus
pesti
short
nonmotil
gramneg
rod
patient
pneumon
plagu
posit
blood
cultur
addit
organ
recov
sputum
lymph
node
aspir
routin
bacteriolog
techniqu
fluoresc
antibodi
stain
sputum
tissu
facilit
rapid
diagnosi
plagu
avail
special
laboratori
potenti
persontoperson
transmiss
patient
plagu
pneumonia
isol
recommend
treatment
consist
gentamicin
doxycyclin
altern
treatment
includ
fluoroquinolon
streptomycin
chloramphenicol
regimen
durat
treatment
minimum
day
catarrhali
caus
pneumonia
acut
exacerb
copd
otiti
media
maxillari
sinus
pneumonia
typic
seen
patient
underli
copd
although
alcohol
malnutrit
increas
age
congest
heart
failur
malign
also
risk
catarrhali
part
normal
upper
respiratori
tract
flora
adequ
screen
sputum
sampl
provid
use
diagnost
inform
purul
specimen
contain
mani
intracellular
gramneg
diplococci
yield
heavi
growth
catarrhali
highli
suggest
true
pneumonia
blood
cultur
rare
posit
mortal
catarrhali
approxim
primarili
due
exacerb
sever
underli
pulmonari
diseas
effect
agent
includ
tmpsmx
cephalosporin
macrolid
tetracyclin
quinolon
inhibitor
combin
virtual
isol
resist
penicillin
ampicillin
product
n
meningitidi
pneumonia
often
surpris
cultur
diagnosi
clinic
manifest
meningococc
pneumonia
resembl
pneumococc
pneumonia
estim
incid
sporad
primari
meningococc
pneumonia
case
per
adult
per
year
pneumonia
also
complic
invas
meningococc
infect
asymptomat
carriag
rate
vari
accord
season
increas
condit
crowd
organ
transmit
persontoperson
larg
droplet
aerosol
nosocomi
cluster
meningococc
pneumonia
well
describ
n
meningitidi
gramneg
diplococcu
appear
sputum
similar
moraxella
acinetobact
rate
isol
organ
blood
cerebrospin
fluid
pleural
fluid
patient
meningococc
pneumonia
highli
variabl
aqueou
penicillin
g
day
daili
dose
million
unit
adequ
therapi
isol
pneumonia
coexist
septicemia
mening
warrant
increas
dose
million
unit
per
day
isol
decreas
suscept
penicillin
yet
signific
problem
unit
state
report
europ
africa
meningococci
transmit
patient
pneumonia
suscept
contact
respiratori
droplet
isol
implement
initi
day
treatment
prophylaxi
ceftriaxon
ciprofloxacin
rifampin
advis
household
intim
contact
patient
includ
health
care
provid
expos
respiratori
secret
pasteurella
multocida
part
normal
oral
flora
mani
domest
wild
mammal
although
skin
soft
tissu
infect
follow
cat
dog
bite
common
manifest
human
infect
sporad
case
pneumonia
lung
abscess
empyema
seen
patient
chronic
respiratori
diseas
includ
copd
carcinoma
bronchiectasi
patient
recal
prior
exposur
anim
pasteurella
pneumonia
indistinguish
etiolog
cap
although
empyema
may
frequent
organ
small
gramneg
coccobacillu
indistinguish
gramneg
rod
gram
stain
identif
organ
cultur
sputum
blood
pleural
fluid
easili
accomplish
treatment
choic
p
multocida
pneumonia
penicillin
g
million
unit
daili
day
tetracyclin
amoxicillinclavulan
secondand
thirdgener
cephalosporin
tmpsmx
fluoroquinolon
chloramphenicol
also
activ
p
multocida
resist
clindamycin
macrolid
may
particularli
difficult
distinguish
radiograph
pyogen
pneumonia
frequenc
noninfecti
etiolog
report
cap
nosocomi
pneumonia
etabl
summar
infecti
noninfecti
caus
nonrespond
pneumonia
diagnost
approach
treatment
failur
requir
complet
reevalu
histori
physic
examin
laboratori
studi
includ
factor
may
relat
delay
respons
reconsider
initi
diagnosi
also
import
compon
diagnost
approach
import
epidemiolog
clue
may
suggest
unusu
microorgan
along
unexpect
resist
antimicrobi
underli
immunodefici
hiv
infect
microbiolog
investig
treatment
failur
requir
comprehens
reexamin
initi
microbiolog
result
togeth
obtain
new
sampl
cultur
assay
etabl
invas
techniqu
ie
bronchoscopi
microbiolog
sampl
local
evalu
airway
recommend
contraind
protect
sheath
brush
bal
sampl
done
procedur
bacteri
cultur
direct
fluoresc
antibodi
stain
nucleic
acid
test
although
cultur
result
may
alter
prior
administr
antibiot
sensit
brush
bal
cultur
approach
nonrespond
cap
patient
undergo
mechan
ventil
tracheal
aspir
provid
diagnost
inform
gram
stain
cytocentrifug
bal
fluid
rapidli
identifi
intracellular
microorgan
may
guid
decis
regard
chang
antimicrobi
therapi
comprehens
microbiolog
studi
also
perform
sampl
nonrespiratori
site
etabl
present
pleural
fluid
obtain
cultur
direct
fluoresc
antibodi
nucleic
acid
test
like
pathogen
role
transbronchi
biopsi
establish
indic
depend
possibl
altern
diagnosi
suspect
chest
radiograph
may
demonstr
complic
pleural
effus
cavit
new
opac
chest
ct
scan
provid
detail
studi
parenchyma
interstitium
pleura
mediastinum
potenti
suggest
specif
microorgan
see
efig
altern
diagnos
patient
applic
risk
factor
appear
nodular
imag
halo
sign
ie
nodul
surround
halo
groundglass
attenu
especi
near
pleura
ct
scan
suggest
pulmonari
aspergillosi
see
chapter
efig
mucormycosi
see
chapter
efig
nodul
similar
appear
also
describ
cytomegaloviru
infect
see
chapter
efig
granulomatosi
polyangi
formerli
wegen
granulomatosi
kaposi
sarcoma
creactiv
protein
also
found
use
predict
inadequ
respons
initi
higher
level
pct
creactiv
protein
repres
risk
factor
inadequ
respons
odd
ratio
wherea
low
level
associ
respons
therapi
recent
describ
biomark
mrproadrenomedullin
shown
greater
associ
sever
assess
level
greater
associ
subsequ
deterior
icu
admiss
caus
nonrespond
pneumonia
classifi
infecti
noninfecti
unknown
origin
etabl
list
common
infecti
noninfecti
caus
patient
hospit
cap
specif
infect
respons
nonrespond
case
frequent
microorgan
found
pneumonia
legionella
p
aeruginosa
aureu
patient
cap
hap
vap
may
fail
respond
resist
empir
antibiot
regimen
select
p
aeruginosa
cover
empir
therapi
cap
caus
case
nonrespond
cap
episod
nonrespond
vap
caus
multiresist
microorgan
frequent
caus
mrsa
p
aeruginosa
carbapenemaseproduc
klebsiella
acinetobact
speci
unusu
microorgan
nonrespond
cap
includ
mycobacteria
nocardia
speci
anaerob
fungi
pneumocysti
jirovecii
organ
requir
antibiot
recommend
cap
hap
efig
investig
etiolog
microorgan
requir
intensifi
microbiolog
diagnost
test
well
exhaust
review
search
risk
factor
includ
epidemiolog
travel
profession
leisur
anim
exposur
person
habit
environment
factor
local
metastat
infecti
complic
also
contribut
treatment
failur
empyema
see
efig
one
frequent
complic
pneumonia
thu
caus
nonrespons
must
evalu
thoracentesi
pleural
effus
present
caus
treatment
failur
abscess
format
see
efig
necrot
pneumonia
see
efig
metastat
infect
endocard
arthriti
pericard
mening
periton
contribut
treatment
failur
common
bacterem
pneumonia
approxim
case
specif
caus
lack
respons
identifi
despit
adequ
antibiot
treatment
may
due
presenc
comorbid
exagger
diminish
inflammatori
respons
noninfecti
diseas
acut
involv
pulmonari
parenchyma
may
simul
pneumonia
includ
pulmonari
infarct
pulmonari
hemorrhag
organ
pneumonia
eosinophil
pneumonia
hypersensit
pneumon
druginduc
lung
diseas
neoplasm
alveolar
cell
lung
cancer
efig
pneumocysti
jirovecii
system
diseas
druginduc
diseas
undertaken
abscess
empyema
drain
result
previou
cultur
review
whenev
possibl
vigor
new
effort
made
identifi
respons
microorgan
specif
antimicrobi
regimen
chosen
depend
patient
risk
factor
diseas
sever
local
epidemiolog
antimicrobi
resist
communityacquir
mrsa
antimicrobi
treatment
may
includ
linezolid
clindamycin
plu
vancomycin
depend
result
suscept
test
nonrespond
nosocomi
pneumonia
combin
three
antibiot
may
necessari
cover
p
aeruginosa
mrsa
endem
flora
hospit
acinetobact
speci
microorgan
increas
spread
virul
carbapenemaseproduc
k
pneumonia
also
necessit
vigil
organ
consider
combin
polymyxin
b
e
tigecyclin
andor
ampicillinsulbactam
occasion
empir
coverag
aspergillu
speci
consid
ie
sever
copd
signific
immunosuppress
therapi
corticosteroid
treatment
especi
support
clinic
radiolog
laboratori
data
recommend
approach
cover
empir
like
causal
microorgan
await
result
repeat
respiratori
sampl
adjust
deescal
antibiot
accordingli
lung
abscess
puscontain
necrot
lesion
lung
parenchyma
result
aspir
bacterialaden
secret
show
airfluid
level
see
fig
lung
abscess
distinct
may
follow
necrot
pneumonia
multipl
small
caviti
develop
contigu
area
lung
lung
abscess
must
distinguish
septic
pulmonari
emboli
often
multipl
bilater
involv
lower
lobe
see
secondari
endovascular
infect
unlik
respiratori
infect
caus
singl
pathogen
lung
abscess
caus
mix
popul
bacteria
common
compon
mix
bacteri
popul
lung
abscess
anaerob
bacteria
princip
peptostreptococcu
speci
term
finegoldia
magna
f
nucleatum
prevotella
melaninogenica
formerli
bacteroid
melaninogenicu
microaerophil
streptococci
viridan
streptococci
also
frequent
isol
contribut
treatment
failur
appropri
antibiot
includ
lung
abscess
may
also
associ
pyogen
bacteria
mycobacteria
fungi
parasit
paragonimu
entamoeba
echinococcu
see
chapter
secondari
lung
abscess
develop
congenit
lung
abnorm
obstruct
neoplasm
foreign
bodi
bronchiectasi
lung
abscess
may
also
complic
pulmonari
infarct
primari
lung
cancer
central
carcinoma
necrosi
metastat
malign
necrot
conglomer
lesion
silicosi
coal
miner
pneumoconiosi
lesion
diseas
granulomatosi
polyangi
formerli
term
wegen
granulomatosi
rheumatoid
arthriti
rheumatoid
nodul
may
also
mimic
lung
abscess
metastas
necrosi
andor
hemorrhag
groundglass
opac
consist
interstiti
pneumonia
suggest
p
jirovecii
pneumonia
nodul
multipl
mass
without
cavit
compat
nocardia
speci
tuberculosi
q
fever
diffus
mix
interstiti
alveolar
opac
may
due
viral
infect
pneumonia
imag
studi
chest
ct
pulmonari
angiographi
consid
evalu
possibl
pulmonari
emboli
defect
relat
host
immun
system
may
imped
recoveri
pneumonia
immunodefici
may
aris
complic
cancer
chemotherapi
immunosuppress
agent
corticosteroid
use
may
result
congenit
eg
agammaglobulinemia
acquir
eg
hiv
infect
immun
defect
mani
immun
defici
remedi
howev
drugrel
immunosuppress
may
improv
discontinu
offend
agent
reduc
dose
although
reduct
immunosuppress
may
promot
recoveri
activ
infect
also
complic
enhanc
inflamm
due
immun
reconstitut
granulocytopenia
absolut
granulocyt
count
less
cellsmm
associ
fulmin
antibioticunrespons
pneumonia
administr
granulocyt
colonystimul
factor
gcsf
granulocytemacrophag
colonystimul
factor
gmcsf
effect
increas
number
circul
neutrophil
despit
effect
neutrophil
routin
administr
gcsf
gmcsf
found
improv
surviv
infect
pneumonia
infect
frequent
associ
poor
clinic
outcom
profoundli
neutropen
patient
use
gcsf
gmcsf
patient
may
justifi
even
though
benefit
demonstr
corticosteroid
treatment
investig
suppress
effect
inflammatori
respons
studi
yield
discord
find
recent
metaanalysi
found
evid
posit
effect
surviv
sever
case
cap
contrast
recent
random
trial
show
benefit
although
number
patient
sever
cap
may
insuffici
reveal
differ
select
group
optimum
therapeut
approach
nonresolv
pneumonia
requir
close
monitor
transfer
higher
level
care
optim
antibiot
regimen
includ
dose
optim
time
make
chang
defin
although
suggest
one
wait
hour
initi
treatment
except
presenc
sever
clinic
deterior
dramat
progress
determin
chest
radiograph
initi
chang
antibiot
new
sampl
obtain
microbiolog
studi
nonrespond
cap
strong
consider
given
extend
antibacteri
spectrum
ensur
coverag
resist
pneumonia
p
aeruginosa
aureu
anaerob
broadspectrum
therapi
vaccin
must
avoid
pregnanc
highrisk
person
chronic
underli
diseas
immunodefici
health
care
staff
take
care
immunosuppress
patient
approv
use
older
year
annual
influenza
vaccin
wide
recommend
immunogen
efficaci
current
avail
vaccin
lower
individu
older
year
age
breakthrough
infect
frequent
two
pneumococc
vaccin
current
avail
purifi
polysaccharid
vaccin
contain
capsular
antigen
isol
preval
capsul
type
immunogen
adult
although
antibodi
level
decreas
prevaccin
level
year
pneumococc
conjug
vaccin
contain
polysaccharid
antigen
preval
capsul
type
conjug
nontox
mutant
diphtheria
toxin
protein
gener
tcell
help
long
live
memori
b
cell
specif
pneumococc
antigen
administ
individu
year
age
older
well
year
age
chronic
condit
increas
risk
invas
pneumococc
infect
eg
diabet
mellitu
chronic
lung
heart
liver
diseas
cigarett
smoke
alcohol
patient
age
year
older
immunodefici
condit
impos
especi
high
risk
invas
pneumococc
infect
asplenia
hiv
congenit
acquir
immunodefici
myeloma
lymphoma
leukemia
chronic
renal
failur
receiv
initi
dose
follow
week
longer
later
etabl
list
condit
indic
administr
pneumococc
vaccin
current
recommend
updat
acip
recommend
administ
seri
adult
year
age
older
dose
receiv
first
follow
dose
month
later
individu
previous
vaccin
given
dose
approxim
year
smoke
risk
factor
pneumococc
diseas
quit
smoke
reduc
risk
idsaat
recommend
smoke
cessat
counsel
well
pneumococc
vaccin
smoker
hospit
pneumonia
clinic
manifest
lung
abscess
distinct
cap
usual
prolong
time
week
month
includ
fever
night
sweat
cough
foulsmel
sputum
fatigu
weight
loss
sometim
hemoptysi
typic
appear
lung
abscess
chest
radiograph
thickwal
caviti
airfluid
level
see
fig
efig
contrastenhanc
ct
occasion
necessari
differenti
lung
abscess
condit
bronchoscopi
may
need
distinguish
lung
abscess
endobronchi
carcinoma
antibiot
activ
anaerob
aerob
bacteria
unaffect
produc
anaerob
mainstay
treatment
lung
abscess
clindamycin
wide
use
superior
penicillin
alon
undoubtedli
increas
preval
product
anaerob
caus
lung
abscess
recent
inhibitor
combin
amoxicillinclavulan
ampicillinsulbactam
found
provid
cure
rate
indistinguish
clindamycin
moxifloxacin
carbapenem
also
use
success
metronidazol
alon
recommend
lack
suffici
activ
microaerophil
streptococci
viridan
streptococci
often
part
mix
microbi
flora
lung
abscess
metronidazol
use
penicillin
ad
cover
streptococci
optim
durat
antibiot
treatment
determin
although
treatment
week
commonli
employ
failur
respond
antibiot
within
day
warrant
investig
altern
diagnos
complic
antibiot
treatment
may
fail
patient
immunodefici
caviti
larg
cm
abscess
due
pyogen
bacteria
p
aeruginosa
aureu
ctguid
percutan
transthorac
tube
drainag
endoscop
drainag
altern
surgic
resect
report
success
rate
procedur
high
although
prospect
control
trial
report
complic
ctguid
tube
drainag
includ
pneumothorax
pyopneumothorax
bronchopleur
fistula
drainag
patient
show
clinic
improv
usual
hour
persist
fever
also
seen
secondari
pleural
empyema
requir
drainag
prevent
pneumonia
may
achiev
administ
influenza
pneumococc
vaccin
recommend
administr
influenza
pneumococc
vaccin
present
etabl
etabl
respect
inactiv
influenza
vaccin
recommend
annual
person
age
month
older
includ
pregnant
women
avers
inject
live
attenu
influenza
vaccin
given
intranas
administr
healthi
person
year
old
live
attenu
inhal
pneumonia
due
legionella
contamin
medic
aerosol
aspir
caus
hospitalacquir
pneumonia
especi
intub
patient
nucleic
acid
amplif
test
use
increasingli
diagnos
virus
fastidi
bacteria
pneumonia
c
pneumonia
l
pneumophila
b
pertussi
cultur
procedur
insensit
slow
relev
therapeut
older
immunocompromis
patient
sign
symptom
pneumonia
may
mute
overshadow
nonspecif
complaint
temperatur
greater
c
accompani
chill
never
attribut
bronchiti
without
examin
chest
radiograph
older
patient
pneumonia
present
alter
mental
statu
without
fever
often
delay
receiv
antibiot
delay
increas
mortal
treatment
pneumonia
pathogendirect
definit
identif
patient
causal
pathogen
may
difficult
therefor
set
patient
resid
eg
commun
hospit
nurs
home
sever
diseas
age
patient
presenc
comorbid
immunosuppress
previou
antimicrobi
therapi
specif
clinic
radiolog
manifest
ill
use
select
initi
empir
antimicrobi
therapi
etiolog
agent
identifi
antimicrobi
regimen
adjust
base
result
vitro
suscept
test
ideal
drug
known
pathogen
narrowest
spectrum
activ
efficaci
least
toxic
least
costli
efigur
lobar
pneumonia
due
pneumococcu
frontal
chest
radiograph
show
homogen
increas
opac
conform
shape
right
upper
lobe
extend
pleural
surfac
associ
air
bronchogram
arrow
find
typic
air
space
consolid
pattern
consist
lobar
pneumonia
commonli
seen
pneumococc
klebsiella
pulmonari
infect
frontal
chest
radiograph
show
sever
nonspecif
small
nodular
opac
bilater
arrowhead
b
axial
chest
ct
lung
base
show
numer
small
centrilobular
nodul
arrowhead
branch
configur
arrow
latter
consist
treeinbud
opac
repres
infecti
bronchiol
appear
small
centrilobular
nodul
branch
configur
specif
haemophilu
influenza
pneumonia
seen
bacteria
occasion
fungi
even
virus
courtesi
michael
gotway
md
b
efigur
mycoplasma
pneumonia
pneumonia
multilobar
pneumonia
frontal
chest
radiograph
show
right
lower
lobe
consolid
arrow
associ
sever
small
nodular
opac
arrowhead
latter
consist
acinar
air
space
nodul
b
axial
chest
ct
lower
lung
display
lung
window
show
extens
bilater
consolid
arrow
associ
small
nodul
arrowhead
vari
mm
cm
size
bronchopneumonia
bronchiol
appear
chest
ct
b
axial
chest
ct
lower
lobe
display
lung
window
patient
swallow
dysfunct
show
numer
small
centrilobular
nodul
branch
morpholog
arrowhead
peribronchi
consolid
arrow
imag
appear
consist
bronchopneumonia
specif
aspir
note
resembl
ct
appear
p
aeruginosa
pneumonia
see
efig
haemophilu
influenza
pneumonia
see
efig
pneumococc
bronchopneumonia
see
efig
courtesi
michael
gotway
md
b
efigur
aspir
bronchopneumonia
rapid
appear
new
lung
opac
imag
depend
lung
involv
frontal
chest
radiograph
perform
admiss
show
clear
lung
sever
day
later
follow
wit
aspir
event
radiograph
b
show
develop
multifoc
peribronchi
nodular
foci
arrowhead
c
lower
thorac
imag
abdomin
ct
scan
sever
week
b
show
minim
basal
atelectasi
e
axial
chest
ct
lower
lobe
perform
immedi
follow
b
show
peribronchi
consolid
arrow
extens
lower
lobe
depend
consolid
e
arrow
note
volum
loss
evidenc
posterior
displac
major
fissur
efigur
infecti
caus
nonrespond
pneumonia
ameb
pleuropulmonari
infect
frontal
chest
radiograph
man
fever
chest
pain
show
right
lower
lobe
consolid
smalltomoder
right
pleural
effus
presum
repres
pneumonia
parapneumon
effus
b
c
axial
chest
ct
patient
fail
respond
therapi
communityacquir
pneumonia
perform
assess
right
pleural
fluid
drainag
follow
thoracostomi
tube
placement
thoracostomi
tube
visibl
posteriorli
b
chest
ct
perform
right
lower
lung
b
show
consolid
central
lowattenu
arrow
latter
consist
pulmonari
abscess
area
necrosi
chest
ct
extrem
lung
base
upper
abdomen
c
show
low
attenu
focu
arrowhead
cranial
liver
l
also
consist
abscess
liver
lung
lesion
close
proxim
one
anoth
suggest
liver
lesion
may
extend
diaphragm
produc
lung
find
behavior
typic
ameb
abscess
evalu
reveal
patient
recent
immigr
unit
state
mexico
stool
analysi
recov
entamoeba
histolytica
trophozoit
efigur
noninfecti
nonrespond
pneumonia
invas
mucin
adenocarcinoma
formerli
refer
mucin
bronchioloalveolar
carcinoma
frontal
chest
radiograph
patient
persist
short
breath
show
right
lower
lobe
consolid
patient
treat
broadspectrum
antibiot
presum
communityacquir
pneumonia
b
repeat
frontal
chest
radiograph
month
follow
show
chang
appear
right
lower
lobe
opac
c
axial
chest
ct
right
lung
base
shown
lung
window
reveal
rel
nonspecif
subpleur
consolid
air
bronchogram
reticul
associ
groundglass
opac
fuse
fdgpet
imag
show
right
lower
lobe
opac
hypermetabol
bronchoscop
evalu
disclos
specif
diagnosi
persist
right
lower
lobe
opac
resect
right
lower
lobe
prove
invas
mucin
adenocarcinoma
courtesi
michael
gotway
md
